

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number  
**WO 01/07098 A2**

(51) International Patent Classification<sup>7</sup>: A61M

(21) International Application Number: PCT/IL00/00424

(22) International Filing Date: 19 July 2000 (19.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/145,095 23 July 1999 (23.07.1999) US  
09/425,233 25 October 1999 (25.10.1999) US

(71) Applicant (*for all designated States except US*): YISSUM  
RESEARCH DEVELOPMENT COMPANY OF THE  
HEBREW UNIVERSITY OF JERUSALEM [IL/IL];  
P.O. Box 4279, 91042 Jerusalem (IL).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): MITRANI, Eduardo  
[IL/IL]; 22 Reuven Street, 93510 Jerusalem (IL).

(74) Agent: EHRLICH, Gal; G.E. Ehrlich (1995) Ltd., 28  
Bezalel Street, 52521 Ramat Gan (IL).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished  
upon receipt of that report.

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: A DEVICE AND METHOD FOR PERFORMING A BIOLOGICAL MODIFICATION OF A FLUID

(57) Abstract: A device for performing a biological modification of a fluid, the device includes (a) a chamber having an inlet for in-  
take of the fluid and an outlet for outflow of the fluid; and (b) a collection of micro-organ cultures of at least one organ for performing  
the biological modification of the fluid, each individual micro-organ culture of the collection including cells and having dimensions,  
such that cells positioned deepest within the individual micro-organ culture are at least about 100 micrometers and not more than  
about 225 micrometers away from a nearest surface of the individual micro-organ culture, thereby *in vivo* organ architecture (organ  
structure) of organ units (e.g., acinus of liver) is maintained within each individual micro-organ culture, the collection of micro-organ  
cultures being located within the chamber and the collection of micro-organ cultures being in contact with at least a portion of the  
fluid flowing through the chamber.



WO 01/07098 A2



## A DEVICE AND METHOD FOR PERFORMING A BIOLOGICAL MODIFICATION OF A FLUID

### FIELD AND BACKGROUND OF THE INVENTION

5       The present invention relates to a device and method for performing a biological modification of a fluid and, more particularly, to an artificial installation, which supplements, augments or replaces organ function. Specifically, the artificial installation may contain liver micro-organ cultures. Further specifically, the artificial installation may contain a viable  
10 kidney micro-organ component. Further specifically, the artificial installation may contain a dialysis component as commonly used in hemodialysis. The kidney micro-organ culture and dialysis unit together perform physiologically as a kidney substitute.

      Further, the present invention relates to a device and method for  
15 supplementing, augmenting or replacing both hepatic and renal function via use of a single artificial installation containing both liver and kidney micro-organ cultures.

      Further, the present invention relates to a device and method for supplementing, augmenting or replacing both hepatic and renal function via  
20 use of a single artificial installation containing both liver and kidney micro-organ cultures in a ratio of approximately 6:1.

      Further, the present invention relates to an artificial installation containing a combined liver and kidney micro-organ culture additionally containing a dialysis component.

25       Further, the present invention relates to a method of preparing viable tissue which can be stored in an artificial installation for supplementing, augmenting or replacing organ function without culturing the tissue prior to storage and for transplantation at a later stage into a host.

      A number of organs in the body, such as the liver and kidney, modify  
30 body fluids such as blood. The kidney is a multifunctional organ, excreting

nitrogenous waste in the form of urea, excreting excess inorganic salts, and actively secreting erythropoietin and other substances, such as, but not limited to rennin and tissue plasminogen activator. The liver removes toxic substances from the blood and performs many biochemical functions such as, but not limited to, detoxifying ammonia into urea, bilirubin metabolism, glycogen storage, lipid synthesis, drug metabolism, albumin secretion and clotting factor secretion. Hepatic and renal functions are closely related, with many metabolic byproducts and toxins passing from the liver, via the circulatory system, to the kidney for excretion into the urine. Thus, the liver and kidney are essential organs, and the synergy between these two organs is crucial. Patients with liver or kidney failure are at high risk for mortality if immediate intervention is not effected.

There are many causes of liver failure, including, for example, exposure to toxic substances, hepatitis, and genetic defects (Kasai, *et al.*, *Artif. Organs*, 18:348-54, 1994). Currently, 70 % of patients with acute liver failure die because of no available treatment (Kasai, *et al.*, *Artif. Organs*, 18:348-54, 1994). Furthermore, 10-30 % of patients die while awaiting donor liver organs (LePage, *et al.*, *Am. J. Crit. Care*, 3:224-7, 1994; Sussman, *et al.*, *Artif. Organs*, 18:390-6, 1994; and Uchino & Matsushita, *Asaio J.*, 40:74-7, 1994).

A bedside life-support device that could temporarily perform liver function during liver failure is called an Extracorporeal Liver Device - ELD. The development and commercialization of such a device would clearly be of enormous benefit for a number of reasons (Fox *et al.*, *Am. J. Gastroenterol.*, 88:1876-81, 1993). An ELD would benefit the roughly 2,000 patients with fulminant liver failure (FH) in the U.S. each year (Hoofnagle, *et al.*, *Hepatology*, 21:240-52, 1995). It could also be used as a bridge to liver transplantation for patients awaiting donor organs.

An ELD that would function for several weeks could in addition allow for recovery to normal functioning of the patient's own liver. Since it



is unlikely that every hepatocyte is destroyed in a damaged liver, adequate liver support for two to three weeks could allow surviving hepatocytes to repopulate the damaged liver. Fewer than a dozen hepatocytes are required to repopulate the liver in an animal model of lethal hepatic disease (Sandgren *et al.*, *Cell*, 66:245-56, 1991). A patient with 90-95% liver necrosis should be able to recover sufficient function to survive independently after only a few days of support (Sussman *et al.* *Artif. Organs*, 18:390-6, 1994).

In an attempt to provide such an ELD, several purely mechanical, non-biological blood-treatment devices have been developed. In the most basic form, the purpose of these devices is to selectively remove toxins and add nutrients across a membrane with a relatively small pore size. One of the most advanced of these non-biological devices has been developed by Hemocleanse™ and has recently received FDA approval. In a randomized, controlled clinical trial using the Hemocleanse™ apparatus, removal of metabolites was limited and there was no significant effect on blood ammonia levels (Hughes *et al.*, *Int. J. Artif. Org.*, 17:657-662, 1994). Clearly, liver function is extremely complex and is unlikely to be replaced by a solely mechanical or a chemical device at this time.

Other currently available ELDs use biological materials as a starting point. For example, one of the most clinically tested device, called ELAD (for extracorporeal liver assist device) uses a transformed immortalized human cell line as a source for hepatocyte-like cells (Sussman, *et al.* *Artif. Organs*, 18:390-6, 1994). Initial trials of this device were performed under "Emergency Use of Unapproved Medical Devices", or "Investigational Device Exemption". Efficacy was not determined, but no serious adverse side effects were observed except for clotting that was managed by drug treatment. While the use of an immortalized human cell line is convenient because it provides an expendable source of cells, there are two major reasons why it may not be ideal. Firstly, there are obvious safety and

regulatory concerns about using immortalized cell lines in clinical practice. Secondly, immortalized cells would not be expected to rein all the normal physiological characteristics of primary hepatocytes, particularly after industrial scale expansion (Sussman *et al.*, *Artif Organs*, 18:90-6, 1994).

5       A second general approach for obtaining liver cells as a source for an ELD, is the isolation of liver cells or tissue from intact livers. In previous attempts, cells from livers have usually been disassociated using enzymes such as collagenase, which disrupts the normal micro architecture of the liver. Some attempts have been used to use liver pieces, but the shape of  
10   these pieces have not been designed for proper surface area to volume ratios necessary for optimal tissue maintenance (Lie *et al.*, *Res Exp Med (Berl)* 185:483-94, 1985).

One current limitation is the ability of current methods of culturing mammalian liver cells to provide conditions which allow cells to assemble  
15   into tissues which simulate the spatial three-dimensional form of actual tissues in the intact organism. Conventional tissue culture processes limit, for similar reasons, the capacity for cultured tissues to express a highly functionally specialized or different state considered crucial for mammalian cell differentiation and secretion of specialized biologically active  
20   molecules of research and pharmaceutical interest. Unlike microorganisms, the cells of higher organisms such as mammals form themselves into high order multi-cellular tissues. Although the exact mechanisms of this self-assembly are not known, in the cases that have been stated so far, development of cells into tissues has been found to be dependent on  
25   orientation of the cells with respect to each other or another anchorage substrate and/or the presence or absence of certain substances such as hormones. In summary, no conventional culture process used in the organ assist devices to date is capable of simultaneously achieving proper functioning of the cells *in vitro* while at the same time maintaining critical  
30   cell/cell/substrate interactions and proper micro-environment to allow

excellent modeling of *in vivo* organ tissue structure and function. The fact that the present invention provides a method for using organ tissue, including liver tissue, in an ELD is an important advancement relative to prior art teachings.

5 This method for using organ tissue, including but not limited to, liver tissue, can rely on cryo-preservation prior or following micro-organ culturing. Components of a suitable cryo-preservation solution might include, but are not limited to, raffinose or trehalose as taught by U.S. Pat. No. 5,879,875 which is fully incorporated herein by reference.

10 In the liver, the unique juxtaposition of diverse cell populations and matrix components in harmony with the angio-architecture results in a delicate bioecological system. It is therefore unlikely that standard cultures of hepatocytes will perform even the minimal liver functions. As mentioned previously, the cells of higher organisms such as mammals form themselves  
15 into high order multi-cellular tissues. An example of physical contact between a cell and a non cellular substrate (matrix) is the physical contact between an epithelial cell and its basal lamina. Examples of functional contact between one cell and another cell include electrical or chemical communication between cells. For example, cardiomyocytes communicate  
20 with other cardiomyocytes via electrical impulses. In addition, many cells communicate with other cells via chemical messages, e.g., hormones, which either diffuse locally (paracrine signaling and autocrine signaling), or are transported by the vascular system to more remote locations (endocrine signaling). Examples of paracrine signaling between cells are the messages  
25 produced by various cells (known as enteroendocrine cells) of the digestive tract, e.g., pyloric D cells which secrete somatostatin which in turn inhibits the release of gastrin by nearby pyloric gastrin (G) cells. This micro-architecture can be extremely important for the maintenance of a tissue explant of an organ in minimal media, e.g., without exogenous sources of  
30 serum or growth factors, because the liver tissue can be sustained in such

minimal media by paracrine and autocrine factors resulting from specific cellular interactions within the micro-organ.

The preparation of such a micro-organ culture is described in U.S. Pat. No. 5,888,720 and U.S. Pat. application No. 08/482,364, both herein  
5 incorporated by reference. In the preparation of a micro-organ culture, the populations of cells which make up the explant are isolated from a liver in a manner that preserves the natural affinity of one cell to another, e.g., to preserve layers of different cells as present in the organ itself. For example, in skin micro-organ cultures, keratinocytes of the epidermis remain  
10 associated with the stroma and the normal tissue architecture is preserved including the hair follicles and glands. This basic structure is common to all organs, for instance, which contain an epithelial and a stromal component. Moreover, such an association facilitates intercellular communication. This is particularly important in differentiating cells where induction is defined  
15 as the interaction between one (inducing) and another (responding) tissue or cell, as a result of which the responding cells undergo a change in the direction of differentiation. Moreover, inductive interactions occur in embryonic and adult cells and can act to establish and maintain morphogenetic patterns as well as induce differentiation (Gurdon, *Cell*,  
20 68:185-199, 1992).

Furthermore, the micro-organ cultures prepared according to U.S. Pat. application No. 08/482,364 preserve normal liver tissue architecture even when cultured for prolonged periods of time. Because these cultures can be maintained in controlled and uniform conditions and yet closely  
25 resemble tissue *in vivo*, they provide a unique continuous source of functional liver cells *in vitro*.

None of the prior art organ assist devices, or related devices in the prior art, uses micro-organ cultures or cryo-micro-organs in order to perform a biological modification of a fluid.

In the United States, approximately 200,000 people develop acute renal failure (ARF). The mortality rate for this group is approximately 50 %. Treatment is limited to supportive care, dialysis and transplantation. Even the continuous dialysis often used in these situations is inadequate. For most patients, timely transplantation is not an option. The National Kidney Foundation estimates there are 53,000 Americans waiting for life-saving transplants; 10 people die each day while waiting.

Another major health care need is in supplementing or replacing kidney dialysis. Unfortunately, current dialysis methods represent a clinically poor and economically expensive solution to kidney failure. Dialysis attempts to replace a highly sophisticated mechanical and regulatory organ with a fairly simple filtering system.

About 250,000 people are treated by dialysis in the United States at a cost of billions of dollars. The ESRD population is growing by 7 % - 9 % per year; by 2010, there will be more than 350,000 such patients. The average cost of providing care for a patient receiving dialysis is US \$ 45,000 per year.

While patients have a more flexible life style with a transplant, and experience greater well being, as noted above, the waiting list for kidney transplants is approximately 50,000. Only about a fifth of those waiting received transplants last year.

Hemodialysis as a mode of treatment has several inherent disadvantages. First, it requires the use of expensive equipment and skilled paramedical personnel to operate the equipment. Second, since treatments are generally conducted several times per week on an outpatient basis, costs are high and patients are required to remain close to their treatment facility. In addition, patients undergoing treatment must remain on a strict diet between treatment sessions, often leading to medical crises due to poor compliance. Each round of treatment lasts several hours and requires venous puncture for connection to the hemodialysis machine. As a result,



some long term hemodialysis patients suffer venous collapse in the most easily accessible veins of the arm.

Kidney transplantation is considered the preferred mode of treatment for patients lacking kidney function, although it has its own set of inherent drawbacks. While routinely performed in many medical centers, it still carries with it all the risks associated with intra-abdominal surgery. In addition, transplant recipients are often treated with immuno-suppressant drugs for a prolonged period after surgery to prevent organ rejection, a practice which places them at increased risk of infection. Most problematic is the chronic shortage of available kidneys for transplantation, and the difficulty in matching donated organs to suitable recipients. Even in the case of a successful transplant, the recipient has only one kidney. Supplementation of the function of a transplanted kidney with a device such as that described in the present invention could increase this post transplantation survival time by reducing the load on the transplanted kidney.

In an attempt to address the chronic shortage of donated kidneys, considerable effort has been directed towards development of genetically engineered humanized pigs to serve as organ donors. Unfortunately, the recent discovery of porcine endogenous retroviruses (pervs) has raised serious doubts about the advisability of xenotransplantation even if it becomes technically feasible. Use of micro-organ cultures isolated physically from the patient, as described, could serve as an enabling technology which would facilitate safe use of these modified porcine organs in humans.

There is thus a widely recognized need for, and it would be highly advantageous to have, a device and method for supplementing, augmenting or replacing liver function, kidney function, or both liver and kidney function, devoid of the above limitations. Such a device and method would allow patients to have a better quality of life while awaiting transplantation

and also serve to increase their life expectancy after receipt of a new organ and in some instances to allow for their own organ to recover while being supported by the device.

U.S. Pat. No. 5,888,720 teaches an *in vitro* micro-organ culture system, and a method for preparing same, for growth of a population of non-fetal animal cells in which epithelial and stromal cells are cultured together in a nutrient medium and remain viable for more than 24 hours. More preferably that patent relates to an *in vitro* micro-organ culture system in which the population is composed of an epithelium and a stroma which are cultured together and maintain the stromal and epithelial tissues, as determined by histology, while remaining viable as determined by DNA synthesis for at least 48 hours in the absence of serum. Most preferably that patent relates to an *in vitro* micro-organ culture system in which epithelial and stromal cells are cultured together and maintain the stromal and epithelial tissues, as determined by histology, while remaining viable as determined by DNA synthesis for at least seven days in the absence of serum. According to the teachings of U.S. Pat. No. 5,888,720, these micro-organ cultures are devoid of an internally disposed synthetic support structure and absent a sandwich support structure.

U.S. Pat. No. 5,888,720 further teaches that the first dimension of the micro-organ culture is not greater than the second dimension and smaller than the third dimension, the first dimension being measured in a direction that is substantially parallel with the exterior surface of the organ from which the micro-organ culture is derived. That patent further teaches that the non-fetal animal cells disposed in the nutrient medium are derived from an organ with an *in vivo* tissue structure including an epithelial tissue and an adjacent stroma, wherein the epithelial tissue has a first surface corresponding to an exterior surface of the organ and a second surface in contact with the stroma. Such a micro-organ culture could be derived from



organs including, but not limited to, lung, duodenum, esophagus, intestine, colon, liver and pancreas.

According to U.S. Pat. No. 5,888,720, the surface area to volume index of the micro-organ culture is defined as "Aleph" where Aleph =  
5  $1/x + 1/a > 1.5 \text{ mm}^{-1}$  and  $x$  = tissue thickness and  $a$  = width of tissue in millimeters. The patent teaches that the first dimension of the micro-organ culture is not greater than the second dimension and smaller than the third dimension wherein the first dimension is no greater than 0.45 mm. The third dimension is ignored in determining the surface area to volume index  
10 because variation in the third dimension causes ratiometric in both volume and surface area. Therefore, when determining Aleph,  $a$  and  $x$  should be defined as the two smallest dimensions of the tissue slice.

This surface area to volume index is a unique aspect of the invention because it allows a similar availability of nutrients to all cells in the tissue  
15 by diffusion. The diffusion of nutrients to every cell in a three dimensional micro-organ culture requires that Aleph is at least approximately  $1.5 \text{ mm}^{-1}$ .

Further according to the teachings of U.S. Pat. No. 5,888,720, populations of cells are grouped in a manner that preserves the natural affinity of one cell to another so that *in vivo* epithelial and stromal tissue  
20 architecture is preserved. For example, in skin micro-organ cultures, keratinocytes of the epidermis remain associated with the stroma and the normal tissue architecture is preserved including the hair follicles. Such an association facilitates intercellular communication. Many types of communication takes place among animal cells. This is particularly  
25 important in differentiating cells where induction is defined as the interaction between one (inducing) and another (responding) tissue or cell, as a result of which the responding cells undergo a change in the direction of differentiation. Moreover, inductive interactions occur in embryonic and adult cells and can act to establish and maintain morphogenetic patterns as  
30 well as induce differentiation (Gurdon (1992) Cell 68: 185-199).

According to the teachings of U.S. Pat. No. 5,888,720, the micro-organ cultures prepared according to the invention as described in Example 1 thereof, comprise a population of cells grouped in a manner which includes a stromal and epidermal layers so as to preserve the natural tissue architecture. This patent teaches preparation of micro-organ cultures from animals including adult human skin, mouse, guinea pig and rat skin have been isolated and grown for up to 21 days in culture. However, it is within the scope of the invention described in this patent to maintain cultures for extended periods of time beyond 21 days and to derive these cultures from other animals. Further, micro-organ cultures from skin and organs including the mammalian, pancreas, liver, kidney, duodenum and esophagus are taught. Similarly, micro-organ cultures of epithelia from mammalian cornea, kidney, breast tissue and various gut derived tissues in addition to the esophagus such as intestine and colon may also be prepared using the methods taught by U.S. Pat. No. 5,888,720.

U.S. Pat. No. 5,888,720 further teaches that these micro-organ cultures can be maintained in a simple medium such as Dulbecco's Minimal Essential in the absence of serum while retaining stromal and epithelial tissues as determined by histology, and cell viability as determined by DNA synthesis. The media and culture may be contained in a culture vessel with an O<sub>2</sub> pressure not substantially greater than that in the atmosphere. Furthermore, the cultures may be grown in a media containing neither sera nor any other biological fluid and can be maintained for extended periods of time for example 48 hours to 21 days.

According to the teachings of U.S. Pat. No. 5,888,720 micro-organ cultures may be maintained in any suitable culture vessel such as a 24 or 96 well microplate and may be maintained at 37 °C in 5 % CO<sub>2</sub>. The cultures may be shaken for improved aeration, the speed of shaking being for example 12 rpm.

In addition, U.S. Pat. No. 5,888,720 teaches methods for production of micro-organ cultures with the properties described hereinabove.

### SUMMARY OF THE INVENTION

5       According to the present invention there is provided a device for performing a biological modification of a fluid, the device comprising (a) a chamber having an inlet for intake of the fluid and an outlet for outflow of the fluid; and (b) a collection of micro-organ cultures of at least one organ for performing the biological modification of the fluid, each individual  
10   micro-organ culture of the collection including cells and having dimensions, such that cells positioned deepest within the individual micro-organ culture are at least about 100 or 150 micrometers and not more than about 225 micrometers away from a nearest surface of the individual micro-organ culture, thereby *in vivo* organ architecture (organ structure) of organ  
15   unit(e.g., acinus of liver) is maintained within each individual micro-organ culture, the collection of micro-organ cultures being located within the chamber and the collection of micro-organ cultures being in contact with at least a portion of the fluid flowing through the chamber.

      According to further features of preferred embodiments of the  
20   present invention the inlet and outlet for the biological fluid take the form of tubes and the device is installed extracorporeal to the patient.

      According to additional further features of preferred embodiments of the present invention the inlet and outlet for the biological fluid take the form of a semipermeable membrane and the device is installed  
25   intracorporeal to the patient in the form of an intrabodily transplantable device.

      Preferably the organ(s) selected includes liver and/or kidney. Also preferably, the collection of micro-organ cultures include cells from the at least one organ, such that intercellular contacts between the cells are

preserved. Most preferably, each of the collection of micro-organ cultures is characterized by an Aleph of at least about  $2.6 \text{ mm}^{-1}$ .

According to preferred embodiments of the present invention, the micro-organ culture is substantially encapsulated by a sheet of a biocompatible polymer, the sheet being located substantially within the chamber. Preferably, the sheet has a first dimension in a range of from about 10 cm to about 90 cm, a second dimension in a range of from about 10 cm to about 90 cm and a third dimension in a range of from about 300 micrometers to about 900 micrometers. Also preferably, a plurality of the sheets are incorporated substantially parallel in orientation within the chamber, such that fluid flows freely between the sheets.

According to another embodiment of the present invention, there is provided a device for performing a biological modification of a fluid of a subject, including: (a) a chamber having an inlet for intake of the fluid and an outlet for outflow of the fluid; (b) a collection of micro-organ cultures for performing the biological modification of the fluid, each individual micro-organ culture of the collection including cells and having dimensions, such that cells positioned deepest within the individual micro-organ culture are at least about 100 or 150 micrometers and not more than about 225 micrometers away from a nearest surface of the individual micro-organ culture, thereby *in vivo* organ architecture of organ units is maintained within each individual micro-organ culture, the collection of micro-organ cultures being located within the chamber and the collection of micro-organ cultures being in contact with at least a portion of the fluid flowing through the chamber; (c) a first tube having first and second ends, the first end for coupling to the subject for receiving the fluid from the subject, the second end for coupling to the inlet; and (d) a second tube having first and second ends, the first end for coupling to the outlet and the second end for coupling to the subject to return the fluid to the subject after the biological modification.

According to still further embodiments of the present invention, there is provided a method of performing a biological modification of a fluid from a subject, the method comprising the step of perfusing a chamber containing a collection of micro-organ cultures with the fluid from the subject, such that the collection of micro-organ cultures performs the biological modification on the fluid, wherein each individual micro-organ culture of the collection includes cells and has dimensions, such that cells positioned deepest within the individual micro-organ culture are at least about 100 or 150 micrometers and not more than about 225 micrometers away from a nearest surface of the individual micro-organ culture, thereby *in vivo* organ architecture of organ units is maintained within each individual micro-organ culture.

According to still further embodiments of the present invention, there is provided a method of preparing a continuous planar organ. The method comprising the steps of (a) obtaining a collection of individual micro-organ cultures of an organ, such that each of the individual micro-organ culture of the collection includes cells and has dimensions, such that cells positioned deepest within the individual micro-organ culture are at least about 100 or 150 micrometers and not more than about 225 micrometers away from a nearest surface of the individual micro-organ culture, thereby *in vivo* organ architecture of organ units is maintained within each individual micro-organ culture; and (b) adding (e.g., layering) a suspension of cells from the organ onto the micro-organ cultures and co-culturing the suspension of cells in presence of the collection of micro-organ cultures, such that the continuous planar organ is formed from an admixture of cells derived from the micro-organ cultures and the cells in suspension.

According to a preferred embodiment of the present invention, the collection of liver micro-organ cultures is provided within a continuous liver planar organ formed by culturing hepatocyte an/or endothelial or other type of cells in presence of the collection of liver micro-organ cultures, such



that the continuous liver planar organ is formed from an admixture of cells derived from the micro-organ cultures and the chosen cells.

According to still further embodiments of the present invention, there is provided a method of preparing a continuous liver planar organ. The method comprising the steps of (a) obtaining a collection of individual liver  
5 micro-organ cultures, such that each of the individual micro-organ culture of the collection includes liver cells and has dimensions, such that cells positioned deepest within the individual micro-organ culture are at least about 100 or 150 micrometers and not more than about 225 micrometers  
10 away from a nearest surface of the individual micro-organ culture, thereby *in vivo* liver architecture of acinus units is maintained within each individual micro-organ culture; and (b) adding (e.g., layering) a suspension of hepatocyte and/or endothelial or other types of cells onto the micro-organ cultures and co-culturing the suspension of cells in presence of the  
15 collection of liver micro-organ cultures, such that the continuous planar liver organ is formed from an admixture of cells derived from the micro-organ cultures and the chosen cells.

According to one aspect of the present invention, there is provided a device for providing a subject with one or more organ functions in case of  
20 impaired organ function, the device comprising a chamber containing a plurality of micro-organ cultures, such that the micro-organ cultures are in contact with at least a portion of said subject's blood as it flows through the chamber, wherein cells positioned deepest within an individual micro-organ culture of the plurality of micro organ cultures are at least about 100 or 150  
25 micrometers and not more than about 225 micrometers away from a nearest surface of the individual micro-organ culture, so that they maintain *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing cells positioned deepest within each individual micro-organ culture benefit of diffusional nutrition and oxygenation thereby  
30 preventing necrosis.

According to an additional aspect of the present invention, there is provided a method for providing a subject with one or more organ functions in case of impaired organ function, the method comprising the steps of: (a) providing a chamber containing a plurality of micro-organ cultures wherein  
5 cells positioned deepest within an individual micro-organ culture are at least about 100 or 150 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing cells positioned deepest within  
10 each individual micro-organ culture benefit of diffusional nutrition and oxygenation thereby preventing necrosis; and (b) forming a fluid communication between the chamber and the circulatory system of the subject, so that blood flows from the subject through the chamber and from the chamber to the subject, such that the micro-organ cultures are in contact  
15 with at least a portion of said subject's blood as it flows through said chamber.

According to additional features of preferred embodiments of the present invention, the chamber of the present invention may be installed extracorporeally.

20 According to additional features of preferred embodiments of the present invention, the chamber of the present invention may be intrabodily transplantable.

According to additional features of preferred embodiments of the present invention, the present invention includes also systems for  
25 supplementing, augmenting or replacing organ function if those systems can rely upon micro-organ cultures as a substitute and become an integral part of their function.

According to additional features of preferred embodiments of the present invention, the present invention includes also methods for



supplementing, augmenting or replacing organ function if those methods rely upon micro-organ cultures as an integral part of their function.

According to additional further features of the present invention, the organ function to be supplemented augmented or replaced is hepatic organ  
5 function.

According to additional further features of the present invention, the organ function to be supplemented augmented or replaced is renal organ function.

According to additional further features of the present invention, the  
10 organ function to be supplemented augmented or replaced is renal and hepatic organ function.

According to additional further features of the present invention, the organ function to be supplemented augmented or replaced includes a dialysis function for excretion of small molecules out of the body.

15 According to additional further features of the present invention, blood enters and leaves the chamber via one or more tubes connected thereto and also to the circulatory system of the subject.

According to additional further features of the present invention, blood enters and leaves the chamber via an outer wall of the chamber which  
20 is constructed of a bio-compatible membrane which facilitates neo-vascularization. Prior to this neo-vascularization, blood enters and leaves the chamber via diffusion.

According to further features of preferred embodiments of the present invention, MCs are further contained within an inner semipermeable  
25 bio-compatible membrane so that plasma from blood in the chamber may diffuse into the membrane and contact the MCs and so that secretions from the MCs may diffuse into blood within the chamber for subsequent return to the circulatory system of the subject.

According to further additional features of preferred embodiments of  
30 the present invention, the bio-compatible membrane is polycarbonate.

According to further features in preferred embodiments of the invention described below, cells derived from a cell suspension are co-cultured with the plurality of micro-organ cultures such that a continuous planar organ is formed.

5 According to additional further features in preferred embodiments of the invention described below, the cells derived from a cell suspension are liver derived cells.

According to additional further features in preferred embodiments of the invention described below, the cells derived from a cell suspension are  
10 kidney derived cells.

According to further features in preferred embodiments of the invention described below, the micro-organ cultures are characterized by being cryo-preserved and thawed before being located within chamber.

According to further features of preferred embodiments of the  
15 present invention, the micro-organ cultures are prepared from a portion of an organ which has been cryo-preserved.

According to further features of preferred embodiments of the present invention, the liver micro-organ cultures are prepared from a portion of a liver which has been cryo-preserved.

20 According to further features of preferred embodiments of the present invention, the kidney micro-organ cultures are prepared from a portion of a kidney which has been cryo-preserved.

According to still further embodiments of the present invention, there is provided a method of preparing cryo-micro-organs, the method  
25 comprising the steps of (a) cryo-preserving at least part of an organ; (b) cutting the cryo-preserved organ into sections while maintaining the resulting sections in a cryo-preserved state; (c) prior to use, thawing the cryo-preserved sections of the cryo-preserved organ; and (d) employing the thawed sections as micro-organs. Such cryo-micro-organs can be

incorporated in a device following thawing or they could be cultured *in vitro* following thawing and then incorporated into the device.

According to further features of preferred embodiments of the present invention, the organ is cryo-preserved in a solution containing at least one component selected from the group consisting of DMEM, DMSO, Glycerin, trehalose, raffinose, an antibiotic, an antimycotic and glucose.

According to additional further features of preferred embodiments of the present invention, the temperature for cryo-preservation of the organ, and for sections cut from it, is between zero degrees centigrade and -180 degrees centigrade.

According to still additional further features of preferred embodiments of the present invention, the thickness of the sections cut from a part of an organ is between approximately 200 and approximately 400 micrometers.

According to still additional further features of preferred embodiments of the present invention, prior to thawing for use as micro-organs, the frozen sections are stored for an additional period of time or are immediately thawed and used.

According to further features of preferred embodiments of the present invention, the employment of the thawed sections as micro-organs is accomplished by (i) providing a chamber; (ii) containing a plurality of the thawed sections within the chamber; (iii) introducing into the chamber at least a portion of a subject's blood so that the plurality of thawed sections are in contact with the at least a portion of a subject's blood, wherein cells positioned deepest within an individual thawed section of the plurality of thawed sections are at least about 100 or 150 micrometers and not more than about 225 micrometers away from a nearest surface of each individual thawed section, thereby maintaining *in vivo* tissue architecture within each individual thawed section, while, at the same time, allowing cells positioned deepest within each individual thawed section of the plurality of micro

organs diffusional nutrition and oxygenation and prevention of necrosis thereof; and (iv) reintroducing into the subject at least a portion of the subjects blood after it has been in contact with the thawed sections.

The present invention successfully addresses the shortcomings of the presently known configurations by providing a device and method for augmenting, supplementing or replacing hepatic function, renal function or both hepatic and renal function in cases where those functions are compromised. In addition, the present invention helps to address the chronic shortage of donated organs for transplant and has the potential to reduce problems of tissue rejection and transfer of disease with transplanted organs. Further, the present invention increases the efficacy with which cell masses in organ assist devices function by providing methods which preserve tissue architecture and methods which eliminate the need for culture in artificial media prior to use, and in particular imposes less stress on the cells during the preparation procedures.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

In the drawings:

FIGs. 1A-1D are diagrammatic sketches of an exemplary bioreactor for housing metabolically active micro-organ cultures;

FIGs. 2A and 2B are diagrammatic sketches of an immunoisulatory  
5 compartment for a micro-organ culture;

FIGs. 3A-3C are diagrammatic sketches of a second bioreactor of the present invention;

FIG. 4 is a diagrammatic sketch of an exemplary operational circuit for a device employing a bioreactor as shown in Figures 1 or 3;

10 FIG. 5 shows the measurement of cell proliferation in several micro-organ cultures;

FIG. 6 shows the measurement of albumin produced by mouse hepatocytes in micro-organ cultures;

FIG. 7 shows the conversion of ammonia into urea in mouse liver  
15 micro-organ cultures;

FIG. 8 shows that human micro-organ liver cultures convert large amounts of ammonia into urea for long periods of time;

FIG. 9 shows that human liver micro-organ cultures are metabolically active;

20 FIG. 10 shows that cryo-preserved micro-organ liver cultures remain functional when grown at 37 °C;

FIG. 11 shows that cryo-preserved human micro-organ liver cultures refunctional when grown at 37 °C;

FIG. 12 shows that mouse liver micro-organ cultures are  
25 metabolically active when encapsulated in alginate sheets;

FIG. 13 shows that mouse liver micro-organ cultures remain functional when cultured in 100% fetal calf serum;

FIGs. 14A and 14B show that rat liver micro-organ cultures are metabolically active when encapsulated in alginate sheets, frozen and then thawed;

FIG. 15 shows that a normal rat can be safely connected to an example of the device of the present invention; and

FIG. 16 shows that an optimal thickness of mouse liver micro-organ cultures is 450 micrometers.

FIG. 17 shows a cross sectional view of another additional system for providing organ function to a patient while simultaneously performing hemodialysis.

FIG. 18 is a plot of ammonia production by kidney MCs as a function of time, comparing media with and without glutamine/Hepes buffer.

FIG. 19 is a plot showing the production of urea and ammonia in kidney MCs according to the present invention in conditions of low and high  $p\text{CO}_2$ . Ammonia production is unaffected by  $\text{CO}_2$  concentration while urea production depends on  $\text{CO}_2$  concentration. T4 time following 4 hours.

FIG. 20A is a plot of  $\text{HCO}_3^-$  concentration as a function of time in cultures of kidney MCs grown in a basic device in the presence of defined culture medium, normal rat blood, and blood from an hepatectomized rat. Basic devices without MCs containing culture medium or in the normal blood were employed as controls.

FIG. 20B is a plot of pH as a function of time in cultures of kidney MCs grown in a basic device in the presence of defined culture medium, normal rat blood, and blood from an hepatectomized rat. Basic devices without MCs containing culture medium or in the normal blood were employed as controls.

FIG. 20C is a plot of partial pressure of oxygen as a function of time in cultures of kidney MCs grown in a basic device in the presence of defined culture medium, normal rat blood, and blood from an



hepatectomized rat. Basic devices without MCs containing culture medium or normal blood were employed as controls.

FIG. 20D is a plot of partial pressure of carbon dioxide as a function of time in cultures of kidney MCs grown in a basic device in the presence of defined culture medium, normal rat blood, and blood from an hepatectomized rat. Basic devices without MCs containing culture medium or in the normal blood were employed as controls.

FIG. 20E is a plot of pH as a function of time in cultures of kidney MCs grown in a basic device in the presence normal rat blood, and blood from an hepatectomized rat.

FIG. 21A is a plot of glucose concentration as a function of time in media of mixed liver and kidney MCs (6:1 ratio) in a basic device. Blood of both normal and hepatectomized rats was used as a media.

FIG. 21B is a plot of  $\text{HCO}_3^-$  concentration as a function of time in media of mixed liver and kidney MCs (6:1 ratio) in a basic device. Blood of both normal and hepatectomized rats was used as a media.

FIG. 21C is a plot pH as a function of time in media of mixed liver and kidney MCs (6:1 ratio) in a basic device. Blood of both normal and hepatectomized rats was used as a media.

FIG. 21D is a plot of partial pressure of oxygen as a function of time in media of mixed liver and kidney MCs (6:1 ratio) in a basic device. Blood of both normal and hepatectomized rats was used as a media.

FIG. 21E is a plot of partial pressure of carbon dioxide as a function of time in media of mixed liver and kidney MCs (6:1 ratio) in a basic device. Blood of both normal and hepatectomized rats was used as a media.

FIG. 22 is a plot of survival percentage as a function of time comparing hepatectomized animals treated with MCs to similar animals treated with the same device but in the absence of MCs. Treatment increased average survival time by ten hours.



FIG. 23 shows RT-PCR results from liver micro-organs before and after perfusion in a device of the present invention. Specific primer pairs for Albumin and clotting factors IX and X mRNA were selected to demonstrate transcription of these liver markers. Lanes 1-4 show a 718 bp band generated using primers specific for Albumin mRNA. Lanes 6-9 show an 821 bp band generated using primers specific for factor IX mRNA. Lanes 11-14 show an 1158 bp band generated using primers specific for factor X mRNA. Lanes 5 and 10 are molecular weight markers. Samples from animal 175 prior to perfusion appear in lanes 1, 6 and 11 and samples from this same animal after 4 hours of perfusion appear in lanes 2, 7 and 12. Samples from animal 176B prior to perfusion appear in lanes 3, 8 and 13 and from this same animal after 4 hours of perfusion appear in lanes 4, 9 and 14.

FIG. 24 is a plot of lignocaine concentration in media of liver MCs grown in culture as a function of time. Decreasing concentration shows metabolism of the drug over time.

FIG. 25A shows the partial pressure of oxygen in rat and pig liver MCs as a function of time. Plots are of MCs perfused with either media or serum as indicated. Pig liver MCs are as efficient or more efficient than rat liver MCs when used to treat an anhepatic rat.

FIG. 25B shows the partial pressure of carbon dioxide in rat and pig liver MCs as a function of time. Plots are of MCs perfused with either media or serum as indicated. Pig liver MCs are as efficient or more efficient than rat liver MCs when used to treat an anhepatic rat.

FIG. 25C shows the bicarbonate ion concentration in rat and pig liver MCs as a function of time. Plots are of MCs perfused with either media or serum as indicated. Pig liver MCs are as efficient or more efficient than rat liver MCs when used to treat an anhepatic rat.

FIG. 25D shows the glucose concentration in rat and pig liver MCs as a function of time. Plots are of MCs perfused with either media or serum

as indicated. Pig liver MCs are as efficient or more efficient than rat liver MCs when used to treat an anhepatic rat.

FIG. 26A shows percent viable cells at time zero and time 120 minutes as assessed by MTT (3-[4,5-Dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide; thiazolyl blue) colorimetric reaction that measures active mitochondrial dehydrogenase in a battery of cryo-preservation solutions (S1-S6). Composition of solutions S1 to S6 is detailed in Table 4 hereinbelow.

FIG. 26B shows percent viable cells at time zero and time 120 minutes as assessed by acridine orange staining in a battery of cryo-preservation solutions (S1-S6). Composition of solutions S1 to S6 is detailed in Table 4 hereinbelow.

FIG. 27A is a plot of carbon dioxide production as a function of time comparing fresh liver MCs to MCs that were preserved in liquid Nitrogen for 72 hours in S4 (see Table 4 for composition of solution S4). Freezing and thawing has no adverse effect on liver MCs.

FIG. 27B is a plot of oxygen consumption as a function of time comparing fresh liver MCs to MCs that were preserved in liquid Nitrogen for 72 hours in S4 (see Table 4 for composition of solution S4). Freezing and thawing has no adverse effect on liver MCs.

FIG. 27C is a plot of pH as a function of time comparing fresh liver MCs to MCs that were cryo-preserved in liquid Nitrogen for 72 hours in S4 (see Table 4 for composition of solution S4). Freezing and thawing has no adverse effect on liver MCs.

FIG. 27D is a plot of glucose concentration as a function of time comparing fresh liver MCs to MCs that were preserved in liquid nitrogen for 72 hours in S4 (see Table 4 for composition of solution S4). Freezing and thawing has no adverse effect on liver MCs.

FIG. 28 is a micrograph depicting colonization of a liver MC by liver endothelial cells previously grown in culture and subsequently co-cultured

with the liver MC. Cultured liver cells express a beta-galactosidase transgene. Visualization is by Lac Z staining so that cells originating in the cell suspension are blue.

FIG. 29 shows *in vivo* functionality of kidney MCs. kidney MCs were transplanted into the peritoneal cavity of a normal rat and were analyzed 48 hours later for expression of rennin, erithropoietin (Epo) and T-PA mRNAs using RT-PCR. As seen, levels of rennin raise after 48 hours, while levels of erithropoietin and T-PA drop. M = 100 bp ladder DNA size marker (Promega).

10

### DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of device for performing a biological modification of a fluid, particularly in order to assist or replace the functioning of an organ which normally performs this modification. As used in this specification and the accompanying claims, the phrase “biological modification of a fluid” refers to a change in the fluid’s biological constituents which are regularly introduced into, removed from or modified within the fluid by secretion, uptake or as a result of a catalytic activity exerted by the organ which normally performs this modification *in vivo* in blood. The device of the present invention is preferably directly connected to or implanted in a subject or patient for performing this modification of the fluid of the subject. As used herein, the terms “subject” and “patient” interchangeably refer to either a human or a lower animal to whom the device of the present invention is connected or in whom the device of the present invention is implanted, or on whom the method of the present invention is practiced.

The principles and operation of a device for modification of a biological fluid according to the present invention may be better understood with reference to the drawings and accompanying descriptions.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is  
5 capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

For purposes of this specification and the accompanying claims, the  
10 terms "micro-organs", "MC", and "MCs" refer to at least one, preferably a plurality of, explants of tissue which retain the basic cell-cell, cell-matrix and cell-stroma architecture of the originating tissue. These terms refer to explants in culture, explants which are cultured and then perfused in a device according to the present invention, and to explants perfused in a  
15 device of the present invention directly without prior culturing. Additionally, these terms refer to explants co-cultured with cells derived from a suspension, and to planar organs formed by co-culture of explants and a plurality of individual cells.

Since the dimensions of the explant are important to the viability of  
20 the cells therein, if the micro-organ culture is intended to be sustained for prolonged periods of time, such as 1-21 days or longer, the dimensions of the tissue explant are selected to provide diffusion of adequate nutrients and gases such as oxygen to every cell in the three dimensional micro-organ, as well as diffusion of cellular waste out of the explant so as to minimize  
25 cellular toxicity and concomitant death due to localization of the waste in the micro-organ. Accordingly, the size of the explant is determined by the requirement for a minimum level of accessibility to each cell in the absence specialized delivery structures or synthetic substrates. It has been discovered, as described in U.S. Pat. application No. 08/482,364, that this

accessibility can be maintained if the surface to volume index falls within a certain range.

This selected range of surface area to volume index provides the cells sufficient access to nutrients and to avenues of waste disposal by diffusion according to existing biological diffusion limits as can be realized by considering the maximum volume to surface area that a developing mammalian embryo can reach before circulation sets in and cells survive by diffusion. These biological diffusion limits can also be realized by noticing that in mammalian epithelium-containing tissues, almost without exception, no cell is approximately more than 400 micrometers from a blood capillary vessel.

This level of accessibility can be attained and maintained if the surface area to volume index, defined herein as "Aleph" or "Aleph index" is at least about  $2.6 \text{ mm}^{-1}$ . The third dimension has been ignored in determining the surface area to volume index because variation in the third

However, when determining Aleph, a and x should be defined as the two smallest dimensions of the tissue slice.

For purposes of this specification and the accompanying claims, "Aleph" refers to a surface area to volume index given by a formula  $1/x + 1/a$ , wherein x = tissue thickness and a = width of tissue in mm. In preferred embodiments, the Aleph of an explant is in the range of from about  $2.7 \text{ mm}^{-1}$  to about  $25 \text{ mm}^{-1}$ , more preferably in the range of from about  $2.7 \text{ mm}^{-1}$  to about  $15 \text{ mm}^{-1}$ , and even more preferably in the range of from about  $2.7 \text{ mm}^{-1}$  to about  $10 \text{ mm}^{-1}$ . Examples of Aleph are provided in Table 1 wherein, for example, a tissue having a thickness (x) of 0.1 mm and a width (a) of 1 mm would have an Aleph index of  $11 \text{ mm}^{-1}$ .

Thus, for example, cells positioned deepest within an individual micro-organ culture or explant are at least about 150 micrometers and not more than about 225 micrometers away from a nearest surface of the

individual micro-organ culture, thereby *in vivo* architecture is preserved while at the same time it is ensured that no cell is farther than about 225 micrometers from the source of gases and nutrients.

**TABLE 1**

5 ***Different values for the surface area to volume ratio index "Aleph", as a function of a (width) and x (thickness) in mm<sup>-1</sup>***

x (mm)	Values of Aleph				
	a = 1	a = 2	a = 3	a = 4	a = 5
0.1	11	10.51	10.33	10.2	10.2
0.2	6	5.5	5.33	5.25	5.2
0.3	4.3	3.83	3.67	3.58	3.53
0.4	3.5	3	2.83	2.75	2.7
0.5	3	2.5	2.33	2.25	2.2
0.6	2.66	2.16	2	1.91	1.87
0.7	2.4	1.92	1.76	1.68	1.63
0.8	2.25	1.75	1.58	1.5	1.45
0.9	2.11	1.61	1.44	1.36	1.31
1.0	2	1.5	1.33	1.25	1.2
1.2	1.83	1.3	1.16	1.08	1.03
1.3	1.77	1.26	1.1	1.02	0.96
1.6	1.625	1.13	0.96	0.88	0.83
2.0	1.5	1	0.83	0.75	0.7

10 For a century the basic structural and functional unit of the liver thought to be the lobule which is a polygonal unit, about 700 micrometers in diameter and 2 mm long. Since the fifties a smaller unit called the acinus



has been recognized as the basic structural and functional unit in the liver. An acinus is a roughly ovoid mass of parenchymal cells arranged around a terminal artery, a venule and a bile duct that branch laterally from the portal area. At either end of the acinus present is a vessel known as the terminal  
5 hepatic venule (this vessel was referred to as the central vein in the old lobule terminology). The acinus is a small unit of about 300-450 micrometers at its smaller dimension, and it includes sectors of two neighbouring classical lobules. It should be pointed out that since its discovery the acinus is known to be the smallest structural and functional  
10 unit of the liver and it also establishes the maximum distance of any liver cell from a source of gases and nutrients. Thus, the micro architecture of the liver as exemplified by the acinus establishes that no cell within the liver is more than about 150-225 micrometers away from a source of nutrients. In fact this is true for any other body organ because, apparently, about 150-  
15 225 micrometers establishes the upper limit of effective diffusion of gases and nutrients. Additional descriptive data of acinus structure and function can be found in any histology text books. For example, in "A text book of histology". Bloom and Fawcett Eds. 12th Edition. Chatman and Hall. N.Y.-London. 1994. Pages 652-656.

20 Without being bound by any particular theory, a number of factors provided by the three-dimensional culture system may contribute to its success. First, the appropriate choice of the explant size, e.g., by use of the above Aleph calculations, provides appropriate surface area to volume ratio for adequate diffusion of nutrients to all cells of the explant, and  
25 adequate diffusion of cellular waste away from all cells in the explant.

Second, because of the three-dimensionality of the explant, various cells can continue to actively grow and most important to fully differentiate and function, in contrast to cells in monolayer cultures, which grow to confluence, exhibit contact inhibition, and cease to grow and divide and  
30 their function is limited. The elaboration of growth and regulatory factors



by replicating cells of the explant may be partially responsible for stimulating proliferation and regulating differentiation and thus function of cells in culture, e.g., even for the micro-organ culture which is static in terms of overall volume.

5 Third, the three-dimensional matrix of the explant retains a spatial distribution of cellular elements, which closely approximates that found in the counterpart organ *in vivo*. Fourth, the cell-cell and cell-matrix interactions may allow the establishment of localized micro-environments conducive to cellular maturation. It has been recognized that maintenance  
10 of a differentiated cellular phenotype requires not only growth/differentiation factors but also the appropriate cellular interactions. The present invention effectively mimics the tissue micro-environment.

***Biological activity of micro-organ cultures:***

The liver micro-organ cultures included in some embodiments of the  
15 present invention are believed capable of performing all classes of the "liver-specific" biological functions. Exemplary functions include the ability to perform ammonia and urea metabolism, and albumin production. These liver-specific biological functions are of particular importance where the cells are to be used in a liver assist device (LAD). For support of  
20 subjects in the form of relatively short term LADS, such as subjects with fulminant hepatic failure (FHF), subjects awaiting liver transplantation, or subjects with non functioning liver grafts, the liver-specific biological functions noted above are believed to be of central importance. However, notwithstanding from the above, there may be others of equal or greater  
25 importance. The other functional deficits can be provided by other means (such as by provision of glucose and monitoring of glucose levels) or do not require acute attention (for example, conjugation of bile acids or bile pigment production, or drug metabolic activity). The levels of liver-specific biological activity "sufficient to support" a subject suffering from hepatic  
30 failure or insufficiency are those which will result in normal or near normal

levels of serum proteins, ammonia conversion to urea, coagulation factors, amino acids, and other metabolites produced in or metabolized by the liver.

These improvements may be measured biochemically or by an improvement in the subject's clinical status. These various molecules, metabolic and clinical parameters and products and the physiological as well as pathological ranges of their concentrations or levels are well known in the art and are set forth, for example, in Zakim & Boyer, Hepatology; A Textbook of Liver Disease, W. B. Saunders Company; Harcourt, Brace, Jovanovich, Inc., Philadelphia, London, Toronto, Montreal, Sydney, Tokyo, (1990), which is hereby incorporated by reference.

The kidney micro-organ cultures included in some embodiments of the device of the present invention are believed capable of performing all classes of the "kidney-specific" biological functions. Exemplary functions include the ability to perform urea metabolism, and secretion of erythropoietin, rennin and vitamin D regulation. Excretion of urea from the body of the subject, while not accomplished by the kidney micro-organ cultures *per se*, is accomplished by the hemodialysis unit of one preferred embodiment of the device of the present invention. Function of that hemodialysis unit is described hereinbelow and examples of its use are detailed in Examples 18 and 19 of the examples section.

***Storage of the Micro-organ cultures:***

The micro-organ culture used as part of the present invention will preferably be prepared and cryo-preserved by gradually freezing them for example in the presence of 10 % DMSO (Dimethyl Sulfoxide) and 20% serum and storing them at -160 °C until required. In a preferred embodiment the liver micro-cultures will be encapsulated into sheets in an semi-permeable matrix such as alginate, as shown in Figure 2B, and cryo-preserved by gradually freezing them for example in the presence of standard culture medium such as Ham's F12 with 10 % DMSO and 20 %

serum. The frozen sheets will then be stored at -160 °C. As an example, the planar sheets containing the micro-organ cultures could be inserted into a sterile synthetic plastic bag sealed on all sides and of dimensions closely similar to those of the sheet. The bag would contain one plastic tubing input at one end and one plastic tubing output at the opposite end of the bag. The plastic bag containing the planar sheet with the micro-organ cultures could then be perfused with standard culture medium such as Ham's F12 with 10 % DMSO and 20 % serum and gradually frozen and stored at -160 °C.

When required, the frozen sheets or the frozen micro-organ cultures will be thawed and assembled into the device of the present invention, preferably on site, and then connected to the system.

According to some preferred embodiments of the present invention, micro-organs can be frozen prior to culturing as is further detailed in the following sections.

Thus, another aspect of the present invention relates to cryo-micro-organs. This aspect of the present invention is based on the discovery that attempts at cryo-preserving an organ or a part of an organ are rather unsuccessful because of the same reason that it is difficult to grow whole organs of parts of them. The reason being small surface area as is compared to the volume of the object in question. Such limitation can be overcome partly by using the natural circulation network existing in the organ in order to perfuse the cells and reach most cells within the organ with appropriate cryo-preservation solution prior to lowering the temperature. Once the organ has been frozen it is not possible to reach all cells through the circulation network since those channels are now frozen. While reducing the present invention to practice it was discovered that if the cryo-preserved organ or a portion thereof is properly cut while still frozen so that a large surface area to volume ratio is achieved while thawing then ensures that all

cells, including those deepest within the micro-organ, will have sufficient rapid access to fluids and to appropriate temperature conditions. this is achieved, for example, by preparing frozen cryo-micro-organs in which the basic epithelial/stromal interaction of the original organ are preserved and  
5 no cell is more than about 500 micrometers, but preferably 300 and most preferably 150 micrometers from a surface. Cutting the frozen organ or a frozen portion thereof into micro-organs can be performed using any suitable cutting device, such as, but not limited to a cryostat or a device including a cutting blade driven either manually or mechanically and  
10 positioned in a chamber pre-cooled to the appropriate temperature.

As an example and in no way limiting the scope of this invention the cryo-micro-organs can be prepared by perfussing an organ with an appropriate cryo-preservation solution using perfusion methods well known in the art. The temperature is then gradually lowered for example at about  
15 one degree per minute. When the tissue reaches a temperature of, for example, between -10 °C and -30 °C, the organ is cut into micro-organs. The micro-organs can be cooled further for storage at, for example, -70 °C, preferably, -100 °C, and more preferably in liquid nitrogen at -196 °C. When the micro-organs are required for use, they can be rapidly thawed, for  
20 example, by dipping them rapidly into an appropriate solution pre-warmed to 37 °C. Since the micro-organs have a large surface area to volume ratio they will thaw quickly, thus reducing the chances of cell damage during the thawing process.

*Use of micro-organ cultures to form continuous artificial planar  
25 organs:*

The present invention is based on the discovery that if the micro-architecture of an organ is maintained and conditions (e.g., its dimensions) are selected to ensure that all cells are within a reasonable distance from a

source of gases and nutrients then the cells can function *ex vivo* similar to as they do *in vivo*.

The experiments described in the examples section below (see example 13) show behaviour of liver MC cultures as a function of thickness. Function was established by the capacity of the liver MC cultures to express a foreign gene when transduced into the cultures *ex vivo*. It is clearly shown that MCs of a thickness of 450 micrometers gave the best results. This data was corroborated by histological examination of the cultures.

Thus, the sheets of MCs according the present invention can be regarded as planar organs, each sheet essentially represents an organ that has been deconvoluted. When removed from the body, normal adult organs lack the system support and circulation necessary to provide adequate exchange of nutrients and gases to each cell in the organ. On the other hand, *ex vivo* planar organs as described herein, ensure (i) that the organ structure is preserved, although in a planar configuration, while at the same time (ii) no cell in the organ is more than about 150-225 micrometers away from the source of nutrients. According to another embodiment of the present invention a continuous planar organ is prepared and used to implement the method and the device according to the present invention.

The continuous planar organ is prepared as follows. A collection of individual micro-organs prepared as described is used as a feeder or substrate layer to support or sustain cells which are derived from the same organ, yet were made into suspension. The feeder layer therefore provides the cells in suspension with a surface onto which they adhere, proliferate and/or differentiate and/or exert their biological functions. Cells derived from the adhered cells together with the collection of individual MCs, eventually produce a coherent and continuous sheet of a planar organ. For example, a continuous liver planar organ is prepared by co-culturing a

collection of individual liver micro-organ cultures and liver endothelial cells.

Thus, the continuous planar organ constitutes a re-engineered coherent organ in which the basic organ microstructure or architecture is maintained. Due to its planar dimensions the continuous planar organ according to the present invention ensures that no cell is more than about 150-225 micrometers away from the source of nutrients, thereby obviating the need for circulation.

It will be appreciated that the concept of using a monolayer of cells as a feeder or substrate layer on which other cell types can be grown is not new and has been used extensively and successfully in the past.

However, the concept of using a collection of micro-organs as a feeder or substrate layer or rather as a "feeder organ" is new and presents several advantages, mainly the fact that the cells grown on the feeder organ are presented with highly complex substrate which is more similar to the substrate encountered by cells as they proliferate *in vivo*.

According to an alternate preferred embodiment of the present invention, kidney micro-organ cultures may be used to prepare a planar organ.

According to an additional alternate preferred embodiment of the present invention, kidney micro-organ cultures may be used together with liver micro-organ cultures to prepare a planar organ with both renal and hepatic function.

According to further features of preferred embodiments of the present invention, a hemodialysis unit may be incorporated within a device of the present invention.

According to additional further features of preferred embodiments of the present invention, a planar organ, or other artificial organ containing micro-organ cultures, may be transplanted into a patient's body instead of being installed extracorporeally.



For purposes of this specification and the accompanying claims, the term "minimal medium" refers to a chemically defined medium, which includes only the nutrients that are required by the cells to survive and proliferate in culture. Typically, minimal medium is free of biological  
5 extracts, e.g., growth factors, serum, pituitary extract, or other substances, which are not necessary to support the survival and proliferation of a cell population in culture. For example, minimal medium generally includes at least one amino acid, at least one vitamin, at least one salt, at least one antibiotic, at least one indicator, e.g., phenol red, used to determine  
10 hydrogen ion concentration, glucose, and at least one antibiotic, and other miscellaneous components necessary for the survival and proliferation of the cells. Minimal medium is serum-free. A variety of minimal media are commercially available from Gibco BRL, Gaithersburg, MD, minimal essential media.

15 The device and method of the present invention may be better understood with reference to the examples, illustrations and drawings given below. Referring now to the drawings, Figures 1A-1C show a bioreactor suitable for use with the device of the present invention. A bioreactor 2 is a chamber 4 having a perfusion inlet 6 and a perfusion outlet 24 with a flow  
20 path for fluid defined therebetween. Fluid flows in through inlet 6, as indicated by arrow 8, and out through outlet 24, as indicated by arrow 10. Preferably, at least one, and preferably a plurality of, perfusion compartments 18 are disposed in the flow path of chamber 4. Each compartment 18 is defined by at least one, and preferably a plurality of,  
25 porous membranes 19. Each compartment 18 contains at least one, and preferably a collection of, micro-organ cultures 20, such as a liver micro-organ culture. There are one or more brackets 16 attached to mounting clamps 14 or other mounting means which hold perfusion compartments 18 in the fluid path of chamber 4. Preferably, a baffle 22 directs the flow of

fluid within chamber 4. The direction of fluid flow within chamber 4 is indicated with arrows. Also preferably, a returner 21 is included for returning at least one product of collection of micro-organ cultures 20 to the subject (not shown).

5 In the embodiment set forth in Figures 1A- 1C, the flow path and pressure about each of perfusion compartments 18 is substantially homogenous.

Accordingly, diffusion across porous membrane 19 into compartment 18 is limited by simple boundary diffusion principles such as concentration  
10 gradients, Brownian motion, etc. Where such diffusion is insufficient, the rate of fluid permeation into chamber 4 can be increased, as for example, by application of a pressure differential across compartment 18. For example, Figure 1D shows bioreactor 2 of Figure 1A reconfigured to provide two distinct flow paths in chamber 4, a "fluid" compartment 4A and a "filtrate"  
15 compartment 4B, with fluid communication occurring only through perfusion compartment 18 and consequently through collection of micro-organ culture 20. In the illustrated bioreactor 2, a pressure differential can be created across perfusion compartment 18, for example, by restricting the flow rate downstream of fluid output 24A such as by the use of a valve.  
20 A positive pressure differential ( $P_{\text{fluid}} - P_{\text{filtrate}}$ ) will create a fluid flow from fluid compartment 4A to filtrate compartment 4B, permitting fluid passing through chamber 4 to be in communication with, and thus biologically modified by, collection of micro-organ cultures 20. In general, output 24B from the filtrate compartment 4B is preferably remixed with  
25 24A from the fluid chamber 4A before returning to the subject.

Suitable matrix materials for forming the micro-organ perfusion compartment include polyamides including nylon such as polycaprolactam and polyhexamethylene adipate, polyamide-imides, polycarbonates, polyacrylates including polymethyl methacrylate and polyethylmethacrylate

and polystyrene. For some applications, suitable matrix materials also be keratin (silk, wool, hair), collagen, of various types, polyolefins such as polyethylene, polypropylene and polybutylene, polyesters such as polyethylene terephthalate and polyethylene adipate, polyurethanes such as polyesterurethanes and polyetherurethanes, glass including glass fibers, stainless steel, silicones, organopolysiloxanes and graphite and combinations thereof. The keratin matrix is keratin, keratin-containing or keratin-like. Others are known in the art. See, for example, US Patent 5,344,454; U.S. Patent No. 4,883,666; U.S. Patent Nos. 4,892,538 and 5,106,627; U.S. Patent No. 4,391,909; and U.S. Patent No. 4,353,888.

Preferably, collection of micro-organ cultures 20 will be encapsulated in a semi-permeable matrix forming an isolatory chamber, such as may be formed from a variety of semi-permeable materials known in the art. The membrane or the like allows passage of nutrients and small vital molecules including oxygen, glucose and hormones between the micro-organ culture and the fluid being treated, but does not allow passage of agents of the immune system such as white cells and, if required, antibodies. As used herein, the term "particle" includes molecules, cells and proteins.

More particularly, when the micro-organ culture is derived from another animal species (i.e., xenogenic with respect to the subject being treated), the pore size must be sufficient to prevent the passage of both inflammatory cells and molecular immunogenic factors from the host into the implant tissue chamber. As used in this specification, "molecular immunogenic factors" refers to molecules such as antibodies and complement. Pore sizes sufficient to block passage of both inflammatory cells and molecular immunogenic factors in humans lie in the range of about 0.015 micron. When the micro-organ cultures are from the same animal species but having a different genetic make up (i.e., allogenic), the pore size usually must be sufficient only to prevent the passage of

inflammatory cells from the host into the implant cell chamber. Pore sizes  
sufficient to block passage of inflammatory cells in humans lie in the range  
of below about 0.8 micron. In most embodiments, it is desirable that the  
micro-organ culture be provided in an immunoisulatory compartment, e.g.,  
5 the pore size and membrane thickness will be selected to provide a  
molecular weight (MW) cutoff of about 10,000 Da to about 250,000 Da,  
such that the molecules which are able to pass have a molecular weight less  
than from about 10,000 Da to about 250,000 Da.

As an illustrative embodiment of such an immunoisulatory  
10 compartment, Figure 2A shows at least one, and preferably a collection of,  
micro-organ cultures 26 disposed in an immunoisulatory compartment 28  
formed by two opposing sheets of semi-permeable membranes 30.  
Collection of micro-organ cultures 26 are placed between two membrane  
sheets 30, or encapsulated into a membrane sheet as shown below (Figure  
15 2B). Opposing clamps 32 are fastened together, such as by a screw or  
screws 34, such that a facing raised ridge 36 of each clamp 32 can be used  
to create a substantially liquid-proof seal around micro-organ culture 26.  
Alternatively and preferably, in place of clamps 32, the edges of membrane  
sheets 30 can be sealed by glue, heat, sonic welding, or other sealing  
20 techniques suitable from the art. More preferably, collection of micro-organ  
cultures 26 is encapsulated directly into a planar alginate sheet of specified  
dimensions. Such a configuration is shown in Figure 2B, with a plurality of  
planar alginate sheets 38. As an example, a planar alginate sheet having a  
first dimension of about 40 cm, a second dimension of about 60 cm and a  
25 third dimension of about 350 micrometers can be prepared. Each such sheet  
could contain about  $1-2 \times 10^{10}$  cells. Thus, in order to obtain approximately  
the same number of cells as a human liver, for example, the number  
of required sheets would be in a range of from about four to about ten  
sheets.

It will be evident that other configurations of the fluid/filtrate embodiment of the subject bioreactor can be used provided for multiple perfusion compartment systems. These configurations can be also be used with one of the sheet configurations described above.

5 For instance, Figures 3A-3C illustrate a basic cartridge 40, which can be linked in tandem with other cartridges 40 to form a bioreactor (not shown) with multiple perfusion chambers. In the exemplary embodiment, a collection of micro-organ cultures 20 is disposed in a perfusion compartment 18. By sandwiching perfusion compartment 18 between two  
10 end plates 42 and 44, with at least one spacer 46 provided therebetween, a fluid compartment 48 and a filtrate compartment 50 can be created on opposing sides of perfusion compartment 18. In operation, fluid entering by at least one, and preferably a plurality of, fluid inputs 52 can flow through fluid compartment 48, and accordingly along a permeable surface of  
15 perfusion compartment 18, exiting fluid compartment 48 via at least one, and preferably a plurality of, fluid ducts 54 which are bores running transversely through perfusion compartment 18. The fluid provided by fluid ducts 54 then exits cartridge 40 via at least one, and preferably a plurality of, fluid outlets 56, which do not permit contact with any fluid in filtrate  
20 compartment 50. In a similar fashion, filtrate fluid entering at least one, and preferably a plurality of, filtrate inputs 58 is communicated directly to at least one, and preferably a plurality of, filtrate ducts 60 without contact with any other fluid in the fluid compartment 48.

However, filtrate ducts 60 discharge the filtrate fluid into filtrate  
25 compartment 50, where it is in direct contact with another (permeable) surface of perfusion compartment 18. Dialysate exits compartment 50 via at least one, and preferably a plurality of, filtrate outputs 62. It will be evident from the present description that fluid from fluid compartment 48 can also permeate perfusion compartment 18, be acted upon by collection of micro-



organ cultures 20, and be returned to filtrate compartment 50 as the metabolic derivative.

In practice, cartridges 40 can be arranged in tandem by rotating the second of two adjacent cartridges by 180 ° such that fluid inputs 52 and  
5 filtrate inputs 58 of a second cartridge 40 are aligned with fluid outputs 56 and filtrate outputs 62, respectively, of a first cartridge 40. Repeating this assembly can provide for a multitude of sequentially linked cartridges 40 having, effectively, one fluid chamber and one filtrate chamber with multiple micro-organ cultures disposed therebetween. By capping, or  
10 otherwise sealing the filtrate inputs for first cartridge 40 of the series, the flow of fluid provided in the filtrate compartment is the result of treated fluid exiting the perfusion chamber.

Figure 4 further illustrates the use of the above described bioreactors 2 of Figures 1-3 in the device of the present invention. For ease of  
15 understanding, the preferred embodiments are described in terms of a liver assist device utilizing liver micro-organ cultures. However, as described above, other organ augmentation can be carried out with the device of the present invention.

Figure 4 shows another embodiment of the device of the present  
20 invention, which preferably includes bioreactor 2 of Figures 1D, 2B or 3A-3C. This embodiment is intended as an example only and is not meant to be limiting. The method of use of this embodiment is also given.

An arterial tube 64 is shown through which blood is delivered from a double lumen venous catheter (or the like) from the subject. Blood flow  
25 into the system is preferably controlled, for example, by a peristaltic pump 66. An anticoagulant, e.g., heparin or the like, is preferably delivered to arterial tube 64 by a syringe 68. Urea, clotting factors, other hepatocyte derived proteins or conversion products, or the like may also be added to the blood. The blood enters an arterial drip chamber 70, where the precolumn



pressure (PI) is monitored. Blood passes out of drip chamber 70 and into bioreactor 2, so that bioreactor 2 (which is the chamber containing the collection of micro-organ cultures here) is perfused with blood from the subject. If desired, a filter or the like (e.g., a commercially available 1 mm mesh filter) may be positioned between drip chamber 70 and bioreactor 2 to prevent clogging of the device. Bioreactor 2 has an inlet tubing set 72 to which the blood from arterial tube 64, with or without the anticoagulant, is delivered. Bioreactor 2, and specifically the collection of micro-organ cultures contained within, processes the blood.

During the passage through bioreactor 2, molecules, preferably of a size of from about 10,000 Da to about 250,000 Da, and most preferably of from about 60,000 Da to about 80,000 Da, are able to diffuse across an immunoisulatory membrane and are exposed to the micro-organ culture. No cellular material from the blood comes into direct contact with the micro-organ culture. Small molecules and proteins less than the molecular weight cutoff pass back into the blood.

Bioreactor 2 delivers the processed (e.g., modified or detoxified) blood to a venous drip chamber 74, which may be part of an air-in-blood detector, and to a venous tube 76. Moreover, the system can monitor pressure in drip chamber 74, which is venous pressure (Pv). Accordingly, the column pressure (PI - Pv) can be calculated.

Plasma is ultrafiltered through the micro-organ culture, preferably simultaneously with blood flow through bioreactor 2,. A pump 78 draws plasma across the micro-organ culture chamber and into the filtrate chamber, where it is collected and passes into a filtrate drip chamber 80 and then through a cell filter element 82, e.g., a 0.45  $\mu\text{m}$  filter, which is provided to ensure that cells or large molecules do not pass into the subject. The pressure (P2) in this chamber 80 is measured, and the membrane pressure (PI - P2) is thus provided. Filter 82 senses and contains any

leakage of cells from the micro-organ culture. The filtrate is then remixed with the blood flow from bioreactor 2. Preferably, the outlet of filter 82 is connected to a first three-port (e.g., Y-shaped or T-shaped) tubing fitting having a fitting for an oxygenator line at one end for connection to an oxygenator so that the fluid is oxygenated.

The filtrate circuit illustrated in Figure 4 accordingly provides for a positive pressure differential across the micro-organ culture compartment in order to enhance flow of serum through the micro-organ culture. Preferably, a pressure sensor 84 can also be situated in-line between arterial tube 64 and syringe 68. Pressure sensor 84 may monitor the pressure of the arterial blood being pumped from the subject to bioreactor 2. Additionally and preferably, a pressure sensor may monitor pressures at the inlet tubing connected to bioreactor 2 after heparin or a like anti-coagulant is pumped into the arterial line. Other pressure sensors are preferably included at the outlet venous line to measure the return of fluid to the subject, as well as in the re-circulation tubing set at various locations for added safety. Thus, the pressure sensors allow for the monitoring of both the access and return pressures of the subject, and the pressure across the device to detect plugging or rupture problems thereof. Furthermore, pressure sensors on each side of filter 82 can monitor for any release of cellular or large particles from the device.

A complete tubing set 86 includes all of the tubing used in the above embodiment. Preferably, tubing set 86 is produced from extruded polyvinylchloride (PVC) tubing or the like of the grade typically employed in systems utilized in hemodialysis, therapeutic plasma exchange, and open heart surgery. The pump segments of the tubing preferably are designed to operate at a blood flow rate of approximately 100 ml/minute to 500 ml/minute, and preferably 250 ml/minute, for approximately 120 hours without developing failure resulting in loss of blood by the subject. The

molded parts utilized in tubing set 86 can comprise rigid PVC, Lexan HP resin or other like material and are designed to exhibit long term high strength bonds to PVC tubing in an environment consistent with uses described above. The sterilization method for tubing set 86 includes  
5 ethylene oxide to yield sterilization of tubing set 86.

As is further shown in Figure 4, a control system 88 controls the overall system operation. Control system 88 may include a number of modules in a single integrated system, or as separate modules. One of the modules operates the dual pump system. Such control modules are  
10 commercially available (e.g., a BSM-22 Dual Pump Blood Safety Module commercially available from CGH, Inc. of Lakew, Colo.).

Another module of control system 88 is an auxiliary monitoring unit (AMU) which is designed to monitor pressures, accept alarm settings from the operator by a keypad or the like, and, in turn, notify the operator if  
15 certain alarm limits are reached. A third module of control system 88 is a Venous Pressure Monitor (VPM) which monitors the pressure in the venous return to the subject in an extracorporeal circuit during treatment. The VPM, also commercially available from CGH, Inc., may include two types of alarms. A first type of alarm has a limiting window such that the alarm is  
20 triggered when the pressure value is 40 mmHg or lower or 70 mmHg or greater than the selected value. A second alarm is a so-called "out-of-range alarm" in which the alarm is triggered when the pressure value is higher than + 450 mmHg or lower than + 10 mmHg. When an alarm is activated, the blood pump stops. The VPM includes pressure transducing elements  
25 and a power supply.

The tubing and connections thereof of the illustrative device are preferably capable of withstanding positive pressure (lumen to exterior) of 3 atmospheres (2,300 mmHg) and negative pressure of 0.75 atmospheres without suffering catastrophic failure or developing leaks between the

interior and exterior of the tubing set. This design results from the consideration that the typical pumps and tubing, used for extracorporeal treatment, reach their delivery limits at about 0.7 atmospheres negative pressure and 1.5 atmospheres positive pressure. The pressure limits  
5 established bracket these limits and provide a reasonable safety margin.

The blood flow rate is preferably adjustable within the range of 0 to 500 mls/minute. The rationale for this is several fold. It is well established that continuous hemodialysis is effective at blood flows of 150 mls/minute. This is to be contrasted with the resting normal renal flow rate of about  
10 1,000 mls/minute. It is believed that the liver has less reserve capacity than the kidneys, and hence the maximum flow rate is a higher fraction of the resting normal hepatic blood flow rate of about 1,500 ml/minute. It is also well established that such extracorporeal flow rates are achievable with standard blood access devices, e.g. single or dual lumen subclavian  
15 catheters. With higher blood flow rates, the therapeutic effect may be enhanced.

The re-circulation flow, e.g., the extraction flow rate, for the re-circulation tubing set is between about 5 ml/min to about 120 ml/minute, and preferably from about 20 ml/min to about 80 ml/min. This flow can  
20 also be defined in terms of a fraction of the blood flow. For example, the extraction flow rate is within a range of from about 5 % to about 30 % of the blood flow rate, and preferably from about 10 % to about 20 % of the blood flow rate. The operator is preferably provided with a table of re-circulation flow rates correlated with blood flow rates, or alternatively it is  
25 envisioned that such could preferably be stored in a memory of controller  
88.

Additionally or alternatively, and preferably, if blood is the fluid being biologically modified, a hemoglobin detector may be utilized in the filtration circuit to indicate any leaks across the micro-organ culture  
30 chamber or chambers. The hemoglobin detector can also serve to indicate

any loss of cells or particles from the extracapillary space as these cells scatter the light and reduce the monitor's output correspondingly. Further, the hemoglobin monitor can be coupled to various alarm circuits to indicate that operator attention is required. The pressure sensors can be incorporated into similar alarm systems, or have an alarm system dedicated thereto. Both the hemoglobin detector and the pressure sensors can be coupled to a controller, and can be used to shut down one or more pumps of the closed loop system. The optical hemoglobin detector is preferably capable of detecting blood losses to the re-circulation line of 1 part packed red cells in 60 parts of plasma. This detection method should preferably operate for both losses which result in intact red cells in the detector or for the specified quantity of cells totally hemolyzed.

Furthermore, the system configuration can be modified to include an arteriovenous fistula in which the pump connected to arterial tube 64 is obviated. Further, the configuration can be adapted for use with a single needle access by adding a reservoir at either end of bioreactor 2 and including a blood pump on the return line. To establish operation of the device of the present invention, ordinary medical procedures are conducted, and equipment setup is believed to be well within the grasp of the ordinarily skilled artisan. Briefly, the operator responsible for the setup of the equipment will load tubing set 86 onto control unit 88, appropriately thread the pump headers into pumps 66 and 78 (if present), attach the pressure monitoring tubing to pressure monitor 74 (if present), set the alarm settings to the values appropriate to the priming mode, fill the anticoagulant (e.g., heparin) syringe 68 with the prescribed heparin dosage, attach heparin syringe 68 to tubing 72, secure heparin syringe 68 to control unit 88, and attach the priming solution to arterial tube 64. The priming solution may be normal saline.



For blood access, the physician in charge of the procedure will establish an appropriate procedure and perform the blood access. This blood access must be capable of delivering the blood flow rate mentioned above required to achieve the desired therapeutic input upon the subject.

5 This blood access must be appropriately anticoagulated by heparin or the like as discussed above. The principles of operation of the device of the present invention depend upon unhindered passage of certain blood borne materials to the perfusion compartment housing micro-organ cultures and similar passage of solutes from the micro-organ cultures to the blood.

10 Compromising this carrying capacity due to inadequate anticoagulation is to be avoided. Of particular concern at the initiation of circulation is coagulation created by stasis within the access during preparation.

The first connection to be made is the subject access line e.g., arterial tube 64. The priming solution is ported into arterial tube 64 at a rate

15 sufficient to ensure that return tube 76 and return line connection are free of trapped air. When the connection is made, flow of priming solution is halted so that the physician can manipulate the tubing to ensure that there is not an unacceptable amount of air at the connection. Arterial tube 64 is then connected.

20 To initiate the procedure, pump 66 is started. Venous tube 76 is unclamped, and heparin is injected. The pressure monitoring chamber levels are examined and adjusted if necessary. To continue the procedure, the operator or attendant personnel should periodically examine the fittings for leaks, the bypass tubing set for evidence of blood cell accumulation, and

25 the monitoring chambers for appropriate levels. The monitoring chamber levels should be readjusted if they vary by more than 0.5 cm from the nominal level, the nominal level being 50 % or higher of the drip chamber. Frequent adjustment of a given monitoring chamber level should motivate the operator to thoroughly examine the tubing for minute leaks. Syringe 68



should be monitored for the amount of anticoagulant remaining and replaced as appropriate.

When the procedure is to be terminated, and the setup broken down, pump 66, and the heparin injection are stopped in turn, and arterial tube 64  
5 clamped. The blood remaining in the system is returned to the subject per protocol using either fluid or air displacement, and venous tube 76 clamped. At this point, control unit 88 with attached tubing set 86 and therapeutic device can be removed from the intensive care unit or area in which it has been used.

10 The above description centered upon the device and method of the present invention. Below are examples of successful preparation of micro-organ cultures which could be used with the device and method of the present invention, as well as an example of *in vivo* use of the device of the present invention. These examples are intended for illustrative purposes  
15 only and are not limiting.

As described in the illustrative examples below, micro-organ cultures from liver, have been isolated and grown for up to 48 days in culture. However, it is within the of the invention to maintain cultures for extended periods of time beyond 48 days.

20 The devices and methods which constitute embodiments of the present invention can all exist in intrabodily transplantable configurations, as well as in the configurations described hereinabove and depicted in Figures 1, 2, 3, 4 and 17. In those intrabodily transplantable configurations, the main wall of the chamber 4 through which blood must flow is  
25 constructed of a semipermeable bio-compatible membrane. This membrane facilitates diffusion of blood components into and of organ secretions out of, the chamber and, via *de novo* angiogenesis, will become vascularized after implantation within the subject. These new blood vessels will supply

blood to the MCs contained within the chamber and also return secreted or metabolized materials to the subject.

The efficiency of devices and methods which constitute embodiments of the present invention can be increased if cells derived from  
5 a cell suspension are co-cultured with micro-organ cultures such that a continuous planar organ is formed. Interactions between the MCs and cells derived from a cell suspension causes the cells derived from a cell suspension to organize to some degree.

As an example, and in no way limiting the scope of the present  
10 invention, the cell suspension may be derived from a population of stem cells. Such stem cells can be, for example, embryonic stem cells which are totipotent and thus have a high probability of responding to the micro-environment of the micro-organ and incorporate themselves as part of the planar organ and differentiate accordingly. The stem cells can be, for  
15 example, bone marrow stem cells, neural stem cells or any other stem cells which have a multiple choice for differentiation depending on the signals it encounters in its micro-environment. These partially organized cells supplement the function of the MC and increase the overall activity of the device.

20 Because of the urgent nature of organ failure, and the unpredictable nature of medical emergencies, it would be advantageous to prepare MCs in advance and store large supplies for later use. According to specific embodiments of the present invention, micro-organ cultures may be cryo-preserved and thawed before being used. Experimental data to this effect  
25 are presented in examples hereinbelow.

Since a limiting step in MC function is the stress induced damage to the structures of the organ pieces during MC preparation, manipulation and storage, specific embodiments which allow direct cryo-preservation of organs and organ pieces without culturing are provided. According to these  
30 embodiments, whole organ or segments derived therefrom are cryo-

preserved and thereafter cryosectioned to thickness of about between 200 and 400 or 450 micrometers in order to create the micro-organs. The frozen MCs may be either stored until required or immediately thawed and used.

This method ensures that the tissues and cells are subjected to minimum stress during the cutting process and allows precise sectioning of the tissue to the required thickness.

Cryo-preservation of organs or segments derived therefrom can be accomplished by a variety of methods known to those ordinarily skilled in the art. One such method of preparing organs for cryo-preservation, provided as a non-limiting example, includes the steps of (a) perfusing the organ *in vivo* with a cryo-preserving solution to replace the blood in the organ with the cryo-preserving solution; (b) removing the organ from the animal into a vessel containing cryo-preservation solution; (c) freezing a portion of the organ and (d) dividing the frozen portion into sections of appropriate size after freezing.

Freezing can be done using any of the standard cryo-preservation techniques commonly known in the art. By way of example, and without limiting the scope of the present invention, a cryo-preservation solution might include DMSO (dimethyl- sulfoxide) in a concentration of about 5 to 30 % in a suitable culture medium such as DMEM. The medium may also be supplemented with trehalose, glucose and other additives known in the art. Cooling of the organ or segment derived from it can be done either gradually or rapidly until the tissue reaches a freezing temperature of below zero degrees centigrade, more preferably a temperature of minus 70 to minus 100 degrees centigrade and most preferably a temperature of minus about 160 degrees centigrade. Gradual freezing to minus 160 degrees centigrade is most easily accomplished by submerging the organs, or segments or sections thereof, in a controlled and gradual manner into liquid nitrogen.

In order to prepare micro-organs from the frozen segments of organs, the segments of appropriate size can be trimmed from the whole organ after freezing, using suitable means. Alternately, they can be trimmed from the organ prior to freezing, either by removing the segment from the donor or  
5 by cutting the segment from the organ after removal of the organ from the donor.

Size of the segments can vary depending on the organ of origin, the intended application, and the subsequent method of preparing MCs from it. As an example, and without limiting the scope of the invention, liver or  
10 kidney segments derived from a whole organ can be cut to rectangular blocks of about 1/2 to several centimeters in width length and depth. These segments are kept frozen and transferred to a suitable cryo-sectioning apparatus where sections of between 200 to about 400 or 450 micrometers in thickness are prepared from the segments while maintaining the cryo-  
15 preserved state of the tissue. A suitable cryo-sectioning apparatus might include, but is not necessarily limited to, a device known in the art as a cryostat or cryo-microtome. A conventional cryostat may require modification so that it can include an appropriate holder to hold the organ/organ segment so that the devise will be able to cut sections of around  
20 200 to 400 or 450 micrometers in thickness. This modification is necessary because cryostats are generally used to prepare thinner sections for histological examination.

Explants derived from the organ or organ segments using the procedure outlined hereinabove will have dimensions of about one half to  
25 several centimeters in length, one half to several centimeters in depth and about 200 to 400 or 450 micrometers in width and would constitute individual micro-organs. Since the micro-organs are kept frozen during preparation, they may be stored or used immediately. Storage can be effected in a suitable device known to one ordinarily skilled in the art such  
30 as a liquid nitrogen bath or a Revco ultra low temperature freezer.

Although primarily liver has been used as an example hereinabove, preferred embodiments of the present invention also include kidney MC devices and methods, and devices and methods which employ both liver and kidney MCs. Other organs are also applicable.

5        Since one of the important functions of the kidney is excretion of small molecules such as urea out of the body, an embodiment which performs this function by means of a dialysis unit incorporated within the device is included as part of the present invention.

Referring now to Figure 17, this embodiment shows a device 112  
10    which contains micro-organs 102 within a semipermeable membrane 110 filled with plasma 116. Within the outer wall of device 112, resides a reservoir of the subject's blood which is flowing through the device. In the pictured extracorporeal embodiment of the device, blood enters via a tube at one end 104 of device 112 and leaves via a tube at the opposite end 106.  
15    Structural integrity is provided by silicon gaskets 116 and polycarbonate plates 119. The entire apparatus is held together with pressure clips (not pictured). Dialysis is accomplished by a dialysis chamber 122 containing a dialysis solution 124 which can absorb small molecules secreted by micro-organs 102 into plasma 116 for outward diffusion through membrane 110,  
20    by virtue of close proximity of dialysis chamber 122 to membrane 110. Dialysis solution 124 is changed, either constantly or periodically, by means of tubes 126 and 128 which are in fluid communication with dialysis chamber 122.

Additional objects, advantages, and novel features of the present  
25    invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

54  
**EXAMPLES**

Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a fashion.

Generally, the nomenclature used herein and the laboratory  
5 procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the  
10 manufacturers' specifications. These techniques and various other techniques are generally performed according to Sambrook *et al.*, molecular Cloning--A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989). The manual is hereinafter referred to as "Sambrook". Other general references are provided throughout this  
15 document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

Reference is made to the following materials and methods, which were employed in experiments described in the following examples.

20 ***MATERIALS AND METHODS***

***Explants for the micro-organ culture:***

Examples of animals from which the liver or kidney micro-organ cultures can be isolated for use in the device of the present invention include humans and other primates, swine, such as wholly or partially  
25 inbred swine (e.g., miniature swine, and transgenic swine), rodents, etc. The source of the liver tissue could be allogenic liver tissue, such as a small lobe of the human liver, which is unsuitable for transplantation, but still contain viable hepatocytes.

A xenogenic source, including, but not limited to, a cow, goat or  
30 preferably a pig organ can also be employed. Although long term exposure



to xenogenic antigens would cause immunological reactions, in the short term, the immune response has not been a problem in initial clinical experience, because the subject's blood cells are prevented from coming into contact with the liver micro-organ cultures. Culture media:

5        There are a large number of tissue culture media that exist for culturing cells from animals. Some of these are complex and some are simple. While it is expected that organ micro-organ cultures may grow in complex media, the cultures can be maintained in a simple medium such as Dulbecco's Minimal Essential Media. Furthermore, although the cultures  
10       may be grown in a media containing sera or other biological extracts such as pituitary extract, neither sera nor any other biological extract is required (See, for example, U.S. Pat. application No. 08/482,364). Moreover, the organ cultures can be maintained in the absence of sera for extended periods of time. Therefore, growth factors need not be included in the media during  
15       maintenance of the cultures *in vitro*.

      However, the addition of such factors, or the inoculation of other specialized cells into the culture, may be used to enhance, alter or modulate proliferation and cell maturation in the cultures. These factors include, but are not necessarily limited to, insulin, growth hormone, somatomedins,  
20       colony stimulating factors, erythropoietin, epidermal growth factor, hepatic erythropoietic factor (hepatopoietin), and liver-cell growth factor, prostaglandins, interleukins, and naturally-occurring negative growth factors, fibroblast growth factors, and members of the transforming growth factor-beta family, liver cells and kidney cells.

25       ***Culture Vessel:***

      The micro-organ cultures may be maintained in any suitable culture vessel and may be maintained at 37 °C in 5 % CO<sub>2</sub>. The cultures may be shaken for improved aeration. The culture vessel may generally be of any material and/or shape. A number of different materials may be used to form  
30       the vessel, including but not limited to: nylon (polyamides), dacron

(polyesters), polystyrene, polypropylene, polyacrylates, polyvinyl compounds (e.g., polyvinylchloride), polycarbonate (PVC), polytetrafluorethylene (PTFE; teflon), thermanox (TPX), nitrocellulose, cotton, polyglycolic acid (PGA), cat gut sutures, cellulose, gelatin, dextran,  
5 etc. Any of these materials may be woven into a mesh.

Where the cultures are to be maintained for long periods of time or cryo-preserved, non-degradable materials such as nylon, dacron, polystyrene, polyacrylates, polyvinyls, teflons, cotton or the like may be preferred. A convenient nylon mesh which could be used in accordance  
10 with the invention is Nitex, a nylon filtration mesh having an average pore size of 210 micrometers and an average nylon fiber diameter of 90 micrometers (#3 -210/36, Tetko, Inc., N. Y.).

#### ***Preparation of Micro-organs:***

Essentially, kidney or liver is removed from suitable normal donor  
15 animals (rats or mice in the case of the examples provided hereinbelow). For small rodents, kidneys are cut in roughly two equal halves by a median section. For big animals and humans, several median sections each of about one to five cm in thickness are performed in order to obtain pieces of an appropriate size. Pieces are then sliced either medially or transversely using  
20 a conventional tissue chopper into explants of about 300 micrometers in thickness. The resultant MCs are then used for *in vitro* cultures, *ex vivo* perfusion and *in vivo* perfusion as described in each of the examples hereinbelow.

#### ***Basic embodiment:***

25 The basic embodiment, hereinafter the basic device, of the present invention, fulfills two very specific criteria: (i) maximum area of contact between the MCs and the fluid to be modified; and (ii) minimum amount of fluid. This basic device is made as follows: micro-organs are layered one next to each other on a polycarbonate sheet of 5 x 25 cm so that the whole  
30 125 cm<sup>2</sup> area is covered by MCs. This constitutes about 3.5 grams of liver

(equivalent to about 30-40 % of the total liver mass from a 300-350 gram rat). This basic embodiment is depicted in Figure 1B, and is described hereinabove. The MCs are overlayed by a second polycarbonate sheet of same dimensions (A assembly). The whole A assembly is introduced into a flat nylon bag of dimensions 5.5 x 25.5 cm to form chamber 4. At one ends, P90 polypropylene tubes 6 and 24 are inserted and both ends are sealed with a thermal sealer. This basic device of the present invention was used in experiments described in examples 15, 16 and 17 described hereinbelow.

***Immunoisulatory embodiment:***

10 The immunoisulatory embodiment of the present invention, hereinafter the immunoisulatory device, (see Figure 2A) is a modified version of the basic device which encloses the MCs contained within the device in a semipermeable membrane 30 so that plasma may cross the membrane to contact the MCs while blood cells are prevented from such contact. Essentially it takes advantage of the blood to deliver oxygen in equal concentrations to all the cells at the surface of any MC whether at the input of the device or as far as the output. A gradient of oxygen concentration is obtained only through the 300 micron thickness of the MCs. The immunoisulatory device also allows for plasma filtration in real time so that red blood cells are driven in a close proximity to the MCs and plasma separation occurs in a milieu that a small distance of several microns, as opposed to millimeters, whereas only a membrane separate s between the red blood cells and the MCs. Thus, the MCs, instead of being in direct contact with blood, are in contact only with plasma. A detailed description of this embodiment is provided herein. In order to connect the device to the animal or patient, blood is drawn from the iliac artery by means of a peristaltic pump. Inside the bioreactor, plasma filters through membrane 30 for processing by the cells in the micro-organs. Processed plasma continuously diffuses out again into the blood surrounding the membrane 30 but contained within chamber 4 of the device. Blood was

15  
20  
25  
30

drawn out of the chambers of the device by means of a second peristaltic pump and back into the jugular vein of the treated subject. This embodiment of the present invention was used in the experiment described in Example 20 hereinbelow.

5       The immunoisulatory device fulfills several very specific criteria: (i) maximum area of contact between the MCs and fluid to be modified; (ii) minimum amount of fluid; (iii) both large surfaces of the MCs in contact with fluid; (iv) real time plasma separation from blood which ensures that oxygen is transported by most efficient carrier i.e., hemoglobin in blood to  
10   close proximity of MCs.

*Dialyzing immunoisulatory embodiment:*

The dialyzing immunoisulatory embodiment, hereinafter the dialyzing immunoisulatory device, illustrated in Figure 17, is a modified version of the immunoisulatory device. It contains all the features of that  
15   device, with the addition of a dialysis unit 122, as commonly used in hemodialysis, which is inserted within the blood containing chamber 108 so that it may dialyze with plasma 116 in the plasma containing chamber 110. In additional embodiments, as pictured, dialysis unit 122 is placed so that it can dialyze both blood 108 and plasma 116. Dialysis unit 122 is filled with  
20   a dialysis solution 124 as commonly used in hemodialysis. This solution may be constantly changed by means of additional tubing 126 and 128 connected to a separate peristaltic pump (not pictured). Alternately, dialysis solution may be changed by periodic flushing through the same additional tubing. This arrangement delivers oxygen in equal concentrations to all the  
25   cells at the surface of any MC whether at the input of the device or as far as the output. A gradient of oxygen concentration is obtained only through the 300 micrometers thickness of the MCs. The device also allows for plasma filtration in real time so that MCs 102, instead of being in direct contact with blood 108, are in contact only with plasma 116. Connection of the

device to the animal is via tubes 104 and 106. An additional circuit driven by two peristaltic pumps drives dialysate fluid into the dialysis unit 122 of the device. Prior to entering the device dialysate fluid passes through a small chamber which allows for gas, glucose and small molecule control.

5 This dialyzing immunoisulatory device fulfills several very specific criteria: (i) maximum area of contact between the MCs and the fluid to be modified; (ii) minimum amount of fluid; (iii) both large surfaces of the MCs in contact with fluid; (iv) real time plasma separation from blood which ensures that oxygen is transported by most efficient carrier i.e. hemoglobin in blood to

10 close proximity of MCs; and (v) by adding a dialysis component it is possible to regulate gases and small molecule concentration by diffusion through the small pores dialysis membrane. This diffusion allows also to filter or dilute out small molecules, which may be toxic. This embodiment of the present invention was employed in experiments described in

15 examples 18 and 19 hereinbelow.

### **EXPERIMENTAL RESULTS**

In the following, Examples 1 through 13 and 21 through 26 relate to experiments conducted on MCs containing only liver tissue. Examples 1 through 12, 22, 23 and 26 describe *in vitro* experiments conducted on MCs

20 containing only liver tissue. Examples 13, 21, 24 and 25 relate to extracorporeal perfusion of liver MCs with blood of a living subject. Examples 14-20 relate to experiments involving kidney MCs. Example 17 demonstrates the use of Kidney and Liver MCs in the same device. Example 20 relates to the use of MCs from one species connected to a

25 second species or subject. Examples 14-17 describe *in vitro* experiments. Examples 18-20 describe perfusion of MCs with blood from a living subject. Examples 27-30 further elaborate the present invention, its advantages and uses.



### ***Example 1***

#### ***Preparation of liver Micro-Organ Cultures***

Mouse micro-organ cultures from liver were prepared as follows. Organs were removed and with scalpels, were cut to an appropriate width of 2 mm, length of 3 mm, and sliced using a tissue chopper or other suitable cutting means into sections of 300 micrometers thick. These micro-organs were placed in a 24-well microplate in 400 ml of Dullbeco's Minimal Essential Medium (DMEM) in the absence of fetal calf serum (FCS) under 5 % CO<sub>2</sub> at 37 °C, under constant shaking at 12 rpm for periods of one to eight days. Twenty micro-explants were grown per well.

### ***Example 2***

#### ***Measurement of Cell Proliferation in Liver Micro-organ Cultures***

Micro-organ cultures from several mouse organs were dissected and cultured in a humidified incubator at 37 °C in the absence of serum using micro-organ cell culture technique, as described in example 1. To assess cell division, incorporation of tritiated thymidine was measured using standard protocols (Kobayashi, *et al.* (1994, J Biomater Sci Polym Ed 6(4):325-42). These results show that DNA synthesis occurs during the culture period (Figure 5). In addition, mouse liver micro-organ cultures were grown as described in example 1 for 14 days and pulsed for 4 hours with bromodeoxyuridine, fixed, and stained with a fluorescent antibody to bromodeoxyuridine to label mitotic nuclei (Sigma Chemical). Nuclei that are actively synthesizing DNA were observed in these cultures (data not shown). This result demonstrates prolonged viability of the MCs *in vitro* and their capacity to proliferate *ex vivo*.

### ***Example 3***

#### ***Albumin is produced by mouse hepatocytes in micro-organ cultures***

Primary mouse hepatocytes grown in micro-organ cultures as described in example 1, remain functional for at least four weeks, as assayed by secretion of albumin and production of urea (see Figure 6).



61

Mouse hepatocytes in micro-organ cultures produce relatively large amounts of albumin as tested both by ELISA and by colorimetric methods (kit No 631, Sigma Chem. Co. St. Louis MO). The histogram shown below displays the amount of albumin secreted per  $10^6$  cells per hour. Note  
5 that even after one month in culture the rate of albumin production remains high, particularly in comparison to two other conventional culture conditions. A is data taken from Nyberg *et al.* (*Cell Transplant*, 2:441-52, 1993) and B data from Shatford *et al.* (*J. Surg. Res.*, 53:549-57, 1992). This result demonstrates that liver MCs retain important physiologic  
10 functions over time.

#### ***Example 4***

##### ***Conversion of Ammonia into Urea in Mouse Liver Micro-organ Cultures***

Mouse liver was dissected and cultured *in vitro* in the absence of serum or exogenous growth factors using micro-organ cell culture technique  
15 as described in example 1. Urea and ammonia were measured from supernatants using standard colorimetric methods using a Urea-Nkit No 640-A (Sigma Chem. Co. St. Louis MO). The data shown in Figure 7 indicates that mouse hepatocytes in micro-organ cultures produce large amounts of urea even after 48 days in culture. As a comparison, Dixit *et al.*  
20 (*Transplantation*, 55:616-22, 1993) have reported values of urea synthesis of 14.6 mg/hour/million cells after 1 day in culture and values of 11.7 mg/hour/million cells after 10 days in culture for micro encapsulated rat hepatocytes *in vitro*. This result demonstrates that liver MCs retain important physiologic functions over time.

25

#### ***Example 5***

##### ***Human micro-organ liver cultures convert large amounts of ammonia into urea for long periods of time***

Human liver micro-organ cultures were prepared as follows. Human liver pieces were obtained from liver wedge biopsies. The pieces were cut  
30 to an appropriate width of 2 mm, length of 3 mm, and sliced using a tissue

chopper into sections of 300 micrometers thick. These pieces were placed in a 24-well micro plate in 0.4 ml of DMEM in the presence or absence of fetal calf serum (FCS) under 5.5 % CO<sub>2</sub> at 37 °C, under constant shaking at 12 rpm. Twenty micro-explants were grown per well. Every two days  
5 the medium was changed and a sample was taken for determination of urea and ammonia. Figure 8 depicts the amount of urea secreted into the medium in arbitrary units but represent values of 10 to 25 micro-grams urea/hour/million cells.

Humans produce 11.2 grams of urea per day and there are at least  
10  $10^{11}$  hepatocytes in a human liver. Thus human hepatocyte cells produce about 5 mg/hour/million cells of urea *in vivo*. It can be seen that human liver micro-organ cultures convert ammonia into urea at about the same rate, if not higher, *in vitro* than the liver cells in the normal *in vivo* situation.

#### ***Example 6***

##### ***Human liver Micro-Organ care metabolically active***

Human liver micro-organ cultures were prepared as described in example 5. Liver MCs converted ammonia to urea in culture. Results are shown in Figure 9. This result demonstrates that human organs retain important physiologic function under the culture conditions of the present  
20 invention for at least 6 days.

#### ***Example 7***

##### ***Cryo-preserved micro-organ liver cultures remain functional when grown at 37 °C***

Micro-organ mouse liver cultures were prepared as described in  
25 example 1 and frozen gradually in 10 % DMSO to -80 °C and then transferred to liquid nitrogen. After several days, the micro-organ cultures were thawed quickly, rinsed and grown for several days in 10 % FCS. Liver cells in micro-organ cultures remain viable and functional as determined by their capacity to transform ammonia to urea even after several days in

culture . The values obtained are shown in Figure 10 and are comparable to those obtained from fresh micro-organ cultures grown in similar conditions. This result demonstrates the feasibility of advance preparation and storage of murine MCs for future use.

5

### *Example 8*

#### *Cryo-preserved human micro-organ liver cultures remain functional when grown at 37 °C*

Micro-organ human liver cultures were prepared as described in example 5 and frozen gradually in 10 % DMSO to -80 °C and then  
10 transferred to liquid nitrogen. After several days, the micro-organ cultures were thawed quickly, rinsed and grown for several days in 10 % FCS. As shown in Figure 11, liver cells in micro-organ cultures remain viable and functional as determined by their capacity to transform ammonia to urea even after several days in culture . The values obtained are comparable to  
15 those obtained from fresh micro-organ cultures grown in similar conditions. This result demonstrates the feasibility of advance preparation and storage of human for future use, an important practical consideration.

### *Example 9*

#### *Liver micro-Organ cultures are metabolically active when encapsulated in 20 alginate sheets*

Mouse liver micro-organ cultures were prepared as described in Example 1. Half of them were encapsulated in a thin sheet (about 400 micrometer-thick) made of alginate. The micro-organ cultures encapsulated in alginate sheets were cultured *ex vivo* in DMEM plus 10 % FCS for 12  
25 days. Every two days the medium was changed and a sample was taken for determination of urea and ammonia. Figure 12 depicts the amount of urea secreted into the medium in arbitrary units but represent values of 10 to 15 micro-grams-urea/hour/million cells. Left is micro-organ cultures alone, right is micro-organ cultures in alginate. This result demonstrates the

feasibility of encapsulation, a potentially important consideration in isolating MCs from human patients during medical use.

***Example 10***

***Mouse liver micro-organ cultures remain functional when cultured in 100 % fetal calf serum***

Micro-organ mouse liver cultures were prepared as described in example 1. Half of the cultures were grown in DMEM and 10 % FCS (left) and the other half were grown in 100 % FCS (right) for five days. Every two days the medium was changed and samples were taken for ammonia and urea determination. Results are shown in Figure 13 and are particularly important because they establish that liver micro-organ cultures not only perform well under *in vitro* conditions but also in the presence of 100 % serum, which is nearer to whole blood and often toxic to cells *in vitro*.

***Example 11***

***Rat liver micro-organ cultures remain functional when encapsulated into planar alginate sheets frozen and stored at -80 °C and further cultured at 37 °C***

Mouse liver micro-organ cultures were prepared as described in Example 1. Half of them were encapsulated in a thin sheet (about 400 micrometer thick) made of alginate. The micro-organ cultures and the micro-organ cultures encapsulated in alginate sheets were frozen gradually in 10 % DMSO to -80 °C and then transferred to liquid nitrogen. After several days, the micro-organ cultures were thawed quickly, rinsed and grown for several days in 10 % FCS. Every two days the medium was changed and a sample was taken for determination of urea and ammonia. Figure 14 depicts the amount of urea (a) and of albumin (b) secreted into the medium in arbitrary units. This result demonstrates that encapsulation of MCs may be performed prior to cryo-preservation without loss of physiologic function upon subsequent thawing and culture.

*Example 12**Determination of optimum thickness of liver micro-organ cultures*

Mouse micro-organ cultures from liver were prepared as follows. Organs were removed and with scissors, were cut to an appropriate width of 2 mm, length of 3 mm, and sliced using a tissue chopper or other suitable cutting means into sections of thickness varying from 150 to 700 micrometers thick. These micro-organs were placed in 35 mm petri-dishes in 2 ml of F12 medium in the presence of 10 % fetal calf serum (FCS) under 5 % CO<sub>2</sub> at 37 °C, under constant shaking at 12 rpm for periods of up to three weeks. Each dish contained micro-organ cultures of a given thickness. Every two days samples were removed and were processed for routine histology and urea production. In addition, after six days in culture the micro-organs were transduced with 10 million CFUs/ml of an adeno-derived viral construct engineered to transcribe the lac-z gene (see, J. Clin. Invest. 90:2598-2607, 1992) Two weeks after transduction, samples were removed, fixed and processed for recombinant  $\beta$ -galactosidase derived  $\beta$ -gal production. Figure 16 shows the amount of  $\beta$ -gal production as a function of thickness. Maximal level of production was obtained when 450 micrometers thick micro-culture organs were employed. Similarly, histology and urea production, measured after three weeks in culture, were both optimal for the 450 micrometers thick micro-culture organs as compared with 150, 300 and 700 micrometers thick micro-culture organs.

*Example 13**Normal in vivo rats can be connected safely to the bioreactor containing liver micro-organ cultures in alginate sheets*

A rat was connected to the prototype described above via cannulation of the right carotid artery and the left jugular vein. Blood was perfused for several hours. Several biochemical parameters were monitored, including of course the well-being of the whole animal. Blood by the micro-organ cultures was reintroduced into the jugular vein assisted by a peristaltic pump

(see Figure 15, photograph with rat outlined for clarity). The animal was kept alive for the duration of the experiment, about 8 hours. This demonstrates the feasibility of using MCs to supplement hepatic function of a live animal.

5

#### ***Example 14***

***Kidney MCs can be cultured for long periods of time in vitro and can regulate pH after a perturbation given 4 days after initiation of culture***

Kidney MCs were prepared as described above and were grown in F-12 containing 2 mM glutamine. After 4 days in culture, the medium was  
10 changed from the cultures by medium containing instead F-12 with 4 mM glutamine and 10 mM HEPES. There is an increase in ammonia production of the cultures even 8 days after initiation of experiment (Figure 20). This shows that the micro-organs remain viable for a prolonged period of time and still are capable of homeostasis i.e., control of pH level.

15

#### ***Example 15***

***Kidney MCs function well in the presence of blood***

Kidney MCs were prepared as described above and cultured for 4 hours inside a basic device (see Materials and Methods, above) without perfusion. In contrast to liver MCs under similar conditions, urea  
20 concentration in kidney MCs drops and ammonia concentration increases as the culture time progresses (Figure 19). This result demonstrates that observed increases in urea concentration for liver MCs are indicative of physiologic function of the liver MC, and are not an artifact of the culture systems as they show activity on both liver and kidney MCs.

25

#### ***Example 16***

***Kidney MCs work well in an ex vivo basic device in the presence of defined culture medium, normal rat blood and in the presence of blood from hepatectomized animal***

Kidney MCs were prepared as described above and cultured for 5  
30 hours in blood from normal animals (+MC N), blood from hepatectomized



animals (+MC HEP) and in F-12 medium containing 2 mM glutamine (+MC MED). As baseline identical basic devices (see Materials and Methods, above) in the absence of MCs were cultured in the presence of same culture medium (-MC MED) or in the presence of normal blood (-MC N) (Figure 20A-E). pH, carbonate ion concentration, O<sub>2</sub> saturation and CO<sub>2</sub> saturation were monitored over time. Kidney MCs performed equally well in culture media and blood from normal or hepatectomized animals. This result confirms that kidney MCs are suited for use in supplementing renal function of a live animal.

10

### *Example 17*

#### *Liver and Kidney MCs function synergistically when combined together in a basic device*

Kidney MCs were prepared as described above. Liver MCs were cultured as described previously. Essentially liver blocks of 8 mm x 8 mm surface were cut from livers of normal adult rats. Explants, 300 micrometer in thickness were cut from the tissue block using a tissue chopper. Thus liver MCs of 8 mm x 8 mm x 0.3 mm were prepared. Kidney and Liver MCs were cultured for 5 hours in a basic device (see Materials and Methods, above) in a proportion roughly equivalent to that in normal animals (i.e., 6 liver per 1 kidney). The basic device was operated *ex vivo*, both in the presence of blood from normal and from hepatectomized animals. There is a significant decrease in pO<sub>2</sub> and a significant increase in pCO<sub>2</sub> as culture time progresses. In spite of this change, a fairly constant HCO<sub>3</sub> concentration is maintained, as a result of the regulatory effect of the kidney MCs (Figures 21A-E). These results demonstrate the feasibility of a mixed MCs device.

25

**Example 18*****Kidney MCs inside a dialyzing immunoisulatory device function well  
when connected to a partially nephrectomized rat***

A rat underwent total nephrectomy of the right kidney and 70 %  
5 nephrectomy of the left kidney. Three hours later the animal was connected  
to a dialyzing immunoisulatory device (see Materials and Methods, above)  
which included a dialysis chamber and a chamber containing kidney micro-  
organs representing 30 % of the kidney mass of the animal. Kidney MCs  
were prepared as described above. As dialysate, F12 medium without  
10 phenol red was used containing 5 % glucose, 30 mg %/ HCO<sub>3</sub> and 1 %  
dextran. The dialysate was flushed continuously with a mixture of 16 %  
O<sub>2</sub>, 5 % CO<sub>2</sub> and air. As shown in Table 2 below the kidney micro-organs  
are biologically active for the total connection time of 4 hours. The rat was  
removed after treatment in coma stage 0. After connection the MCs were  
15 removed from the bioreactor, RNA was prepared and the MCs were tested  
by RT-PCR for transcription of the erythropoietin gene. MCs continue to  
transcribe erythropoietin at about the same levels after being connected to a  
nephrectomized animal as at time zero. This result further confirms that  
kidney MCs are suited for use in supplementing renal function of a live  
20 animal.

**Table 2**

	<b>Time (hr)</b>	<b>pO<sub>2</sub>artery</b>	<b>pO<sub>2</sub>dialysate</b>	<b>pO<sub>2</sub>bioreactor</b>
	0	113.2		73.9
25	1	103.4	159.3	100.8
	2	102.6	151.2	110
	4	112.6	147.1	114.3

		69		
		pCO <sub>2</sub> artery	pCO <sub>2</sub> dialysate	pCO <sub>2</sub> bioreactor
5	0	35.5		37
	1	39.9	18.0	37.4
	2	39.2	19.6	37.0
	4	39.1	21.8	38.7
		Glucose-artery	Glucose-dialysate	Glucose-bioreactor
10	0	96	-	97
	2	114	106	74
	4	103	112	87

*Example 19*

*A partially nephrectomized rat remains fully active after a second connection to Kidney MCs inside a dialyzing immunoisulatory device*

After 24 hours, the animal described in example 18 was reconnected to the kidney containing dialyzing immunoisulatory device as described in example 18. Conditions were the same as in previous example except that a 2 % dextran solution was used instead. The animal was released in stage 0 and the physiological parameters were normal throughout the duration of the experiment. This demonstrates the feasibility of using the kidney MCs 24 hours after it has been prepared. This result confirms that kidney MCs are suited for use in supplementing renal function of a live animal. This result demonstrates that kidney MCs are suited for use in supplementing renal function of a live animal even if only attached to the animal periodically.

**Example 20*****Pig liver MCs incorporated into an immunoisulatory device function well  
when connected to a xenogenic rat***

Pig liver MCs were prepared in exactly the same conditions as those  
5 described in example 17, except that the source of tissue was a pig liver.  
The immunoisulatory device (see Materials and Methods, above) containing  
the pig liver MCs was connected to a normal rat. The rat treated under such  
conditions showed no adverse side effects. Furthermore, the pig liver-  
derived MCs were found to be more active as judged by oxygen  
10 consumption and glucose production than rat MCs. It was also found that  
use of the pig MCs in the device to treat rat animals had no adverse effect  
on the pig MCs either. The MCs were tested by MTT at time zero, after  
four hours of use in the device connected to a normal rat and after culturing  
them an additional eighteen hours *in vitro* in the presence of F-12 medium.  
15 Very high levels of MTT activity were found which were indistinguishable  
in all three conditions. In addition cell viability as assayed by acridine  
orange incorporation and examination under an UV microscope showed  
viability of > 90 % in all three cases.

Figures 25A-D show that the porcine MCs were at least as efficient  
20 as the rat MCs with respect to regulating pressure of Oxygen/Carbon  
Dioxide balance, carbonate ion concentration and glucose concentration.  
This was true in both culture media and rat serum.

These results suggest the feasibility of using porcine liver to treat  
non-porcine mammals.

25

**Example 21*****A liver MC device significantly prolongs the life of 92 % of  
hepatectomized rats***

In a controlled experiment *in vivo*, twelve hepatectomized rats were  
treated with a liver MC containing device according to the present  
30 invention (Figure 22; treated). An additional ten hepatectomized rats were

treated in identical conditions except that the device contained no MCs (Figure 22; control). Treatment duration was four hours. Animals were released and kept for observation until death occurred after treatment. Figure 22 shows that use of an MC containing device improved survival  
5 time by an average of 10 hours. This result was significant using standard t-test distribution ( $P < 0.05$ ).

### *Example 22*

*Liver MCs transcribe Albumin and clotting factors IX and X messenger  
RNAs at normal in vivo levels during and after perfusion in a device  
10 connected to 92 % anhepatic rats.*

Liver MCs remain functional after perfusion in a device of the present invention and transcribe Albumin and clotting factors IX and X mRNA as illustrated by RT-PCR as follows.

Reverse transcription was effected by incubating 1 µg RNA (about  
15 10 µl), 0.5 µg of Oligo-dT (1 µl, Promega) and RNase free H<sub>2</sub>O (In a total volume of 15 µl) for 5 minutes at 70 °C. The mixture was cooled on ice and the following ingredients were added: 5 µl RT buffer (Promega), 5 µl of dNTPs mix (10 mM, Promega), 20 units of RNAsin (Promega) and 100 units of MLV-Reverse Transcriptase (Promega). RNase free H<sub>2</sub>O was  
20 added to a final volume of 50 µl. The reactions were incubated at 42 °C for 60 minutes.

For PCR amplification a mixture containing 2.5 µl of 10x reaction buffer, 0.2 mM dNTPs, 1.5 mM MgCl<sub>2</sub>, 2 µl single strand DNA from RT reaction, 0.6 mM (1 µl) of each primer (upstream and downstream), 2.5  
25 units (0.5 µl) *Taq* DNA polymerase (Promega) and H<sub>2</sub>O to complete the volume to 25 µl were mixed. Cycling conditions were: first cycle - 94 °C 60 seconds, TM °C 60 seconds and 74 °C 5 minutes; second to 34th cycle - 94 °C 45 seconds, TM °C 60 seconds and 74 °C 2 minutes; last cycle - 94 °C 60 seconds, TM °C 60 seconds and 74 °C 5 minutes, wherein TM is the

melting temperature characterizing each pair of amplification primers as is further detailed below.

The following amplification primer pairs were employed. For amplification of a 678 bp product of Albumin cDNA Alb1 5'-  
5 TGAAGTGGCTGACTGCTGTG-3' (SEQ ID NO:1) and Alb2 5'-  
CATCCTTGGCCTCAGCATAG-3' (SEQ ID NO:2) having  $T_M$  of 45 °C  
were employed. For amplification of a 821 bp product of clotting factor IX  
cDNA IX1: 5'-TCTGTTGCCTACAATTCT-3' (SEQ ID NO:3) and IX2  
5'-TAGTATATATTCCATATT-3' (SEQ ID NO:4) having  $T_M$  of 42 °C  
10 were employed. For amplification of a 1158 bp product of clotting factor X  
cDNA X1: 5'- ATAAAGAAAGGAAATCTG-3' (SEQ ID NO:5) and X2  
5'- TCACAAAGTAGGTGTCTT-3' (SEQ ID NO:6) having an average  
15  $T_M$  of 46 °C were employed.

All PCR products were electrophoresed through a 1.5 % Agarose gel  
15 (BRL) in 0.5 X TBE at room temperature under 100 V. The results are  
shown in Figure 23.

In Figure 23, lanes 1-4 show a 718 bp band generated using primers  
specific for Albumin mRNA. Lanes 6-9 show an 821 bp band generated  
using primers specific for factor IX mRNA. Lanes 11-14 show an 1158 bp  
20 band generated using primers specific for factor X mRNA. Lanes 5 and 10  
are molecular weight markers.

Samples from animal 175 prior to perfusion appear in lanes 1, 6 and  
11 and from this same animal after 4 hours of perfusion appear in lanes 2,7,  
and 12. Samples from animal 176B prior to perfusion appear in lanes 3, 8  
25 and 13, and from this same animal after 4 hours of perfusion appear in lanes  
4, 9 and 14. Both animals transcribed all 3 liver genes after perfusion  
indicating that the liver MCs retain their complex physiologic function  
during the perfusion process.



*Example 23**MCs cultured ex vivo in controlled conditions show P450 function by**Lignocaine consumption*

As an additional indicator of liver function in MCs cultured *ex vivo*,  
5 metabolism of lignocaine was assayed (Figure 24). Concentration of  
lignocaine in culture medium declined for 30 hours, indicating P450  
function in lignocaine uptake by liver cells of the micro-organ cultures.

The following materials were employed. DMEM medium; HEPES;  
penicillin-streptomycin solution (10,000 units, 10 mg/ml) were from  
10 Biological Industries Ltd., Israel. Glycine; glucose; glutamine; insulin;  
hydrocortisone were from Sigma Israel. Lignocaine (Esracain 2 %  
lignocaine-HCl, 200 mg/ml) were from Medical Laboratories Ltd., Israel.

Four Lewis rat liver derived MCs per ml of DMEM medium (without  
phenol red) supplemented with 2 mM glutamine, 10 mM HEPES, antibiotic  
15 solution 1/500 (vol:vol); 3 mM glycine; 2 grams/liter (w:vol) glucose; 1  
mg/% (w:vol) insulin; 7.5 µg/ml hydrocortisone and 80 µg/ml (w:vol) of  
lignocaine which was added to the culture medium at the beginning, were  
cultured for 48 hours at 37 °C in a humidified 5 % CO<sub>2</sub>/95 % air incubator  
(Forma Scientific). Thereafter, 100 µl of medium samples were taken at the  
20 time described bellow into sterilized ependorf tubes and centrifuged at  
2,000 rpm after which samples were stored at -20 °C until assayed with the  
TDx/TDxFLx Lignocaine assay using Fluorescent Polarization  
Immunoassay using commercially available reagents and the procedure by  
Pape B.E. et al; Clinical Chemistry 24(11):2020-2922, 1978. The results  
25 are summarized in Table 3 hereinbelow.

74  
**Table 3**

	TIME (hours)	LIGNOCAINE-HCl $\mu\text{g/ml}$
T0-10.50 AM	0	62.2
T1-18hsPM	7.1	33.9
T2-11hsAM	24.1	23.7
T3- 17hs PM	30.1	20.9

***Example 24***

***MC containing devices prevent Anhepatic rats from deteriorating when  
connected for up to 13 hours.***

Anhepatic rats were reverted from coma stage II to coma stage I, and even to stage 0 after being connected to a device according to the present invention which contained liver MCs. These rats remained in that stage through the whole perfusion period of up to thirteen hours. These results demonstrate potential clinical utility for the present invention in cases of liver failure.

***Example 25***

***Liver MCs remain functional after cryo-preservation***

A series of different cryo-preservation solutions (Table 4) were prepared and tested. MTT and Acridine orange staining were employed to assess cell viability after cryo-preservation for 72 hours and thawing (Figure 26A and B). A solution (S4) containing 20 % DMSO and 100 mM Trehalose was deemed most efficacious by these criteria and was used in further studies. Cryo-preserved MCs were found to show comparable performance to freshly prepared MCs when tested *ex vivo* with respect to carbon dioxide production, oxygen consumption, pH regulation and glucose production (Figures 27A-D).

**Table 4:*****Optimization of MC Cryo-preservation conditions\*:***

SAMPLE 1 (S1): 20 % DMSO
SAMPLE 2 (S2): 20 % GLYCEROL
SAMPLE 3 (S3): 10 % DMSO, 10 % GLYCEROL
SAMPLE 4 (S4): 20 % DMSO, 100mM TREHALOSE
SAMPLE 5 (S5): 20 % GLYCEROL, 100mM TREHALOSE
SAMPLE 6 (S6): 10 % DMSO, 10 % GLYCEROL, 100mM TREHALOSE

\*Liver MCs were frozen in liquid N<sub>2</sub> for 72 hours in each of solutions S1-S6.

These cryo-preservation methods are significant for three reasons. First, they allow preparation of MCs at a central facility. Large batches of MCs may be prepared and cryo-preserved. Samples from each batch may be thawed and tested for performance prior to distribution and use.

Second, MCs stored in liquid nitrogen can be assembled into a functional biodevice in a matter of less than an hour. This fact is critical for treating patients with acute organ failure.

Third, human organs which are donated for transplantation, but are not transplanted, may be stored indefinitely in this fashion for subsequent use. Use of this method in conjunction with an immunoisulatory device as described hereinabove can help eliminate problems of organ rejection and increase the percentage of donated organs actually used.

***Example 26******Preparation of liver planar organs***

Primary liver mesenchymal cells were harvested from transgenic Rosa 26 mice (see Kennedy et al. (1997) Blood, 1,90(3):986-93.) expressing the  $\beta$ -galactosidase gene through a constitutive promoter. These transgenic  $\beta$ -galactosidase expressing cells can be identified after implantation into MCs via a simple colorimetric reaction.

Transgenic mesenchymal cells were seeded onto primary liver MCs and incubated further under appropriate conditions. As shown in the Figure 28, the transgenic cells (blue) became incorporated into the MCs. This result demonstrates the possibility of preparing planar organs integrated  
5 from a plurality of MCs joined by mesenchymal cells.

### *Example 27*

#### *Cryo-micro-organs appear to function as well as fresh micro-organs*

To assay the functionality Cryo-micro-organs as is compared to fresh micro-organs four experiments were conducted. Cryo micro-organs  
10 prepared according to the teachings of the present invention. Rat livers were perfused with modified Krebs solution and MEM alpha solution. The liver lobes were separated and cut to 0.8 cm blocks. The blocks were kept in ice for 30 minutes and transferred to -15 °C. The frozen blocks were cut to 300 micrometers sections using a Leitz cryostat at a temperature of -15  
15 °C. The sections were then transferred onto ice for 30 minutes and thereafter frozen using liquid nitrogen in a slow freezing procedure (-1 °C/min). They were then thawed by quick immersion into DMEM (4 MC's per 1 ml) containing 10 % fetal calf serum at 37 °C and then cultured at 37 °C. In parallel, fresh micro-organs were prepared and grown as a control.  
20 All experiment were performed in petri dishes at 4 MC's per 1 ml of FCS.

In a first experiment (Table 5) cryo-preserved MCs prepared from cryo-preserved tissue were grown in petri-dishes. In a second experiment (Table 6) cryo-preserved MCs prepared from cryo-preserved tissue were grown in a device as described in Figure 17. In a third experiment  
25 (Table 7) cryo-preserved MCs prepared from fresh tissue were grown in standard petri dishes. Whereas, in a fourth experiment (Table 8) fresh MCs prepared from fresh tissue were grown in standard petri dishes. As shown in tables 5-8 below, several factors indicative of liver function were monitored under these four experimental setups, respectively. No gross

77

changes in MC function were apparent under these four different experimental conditions.

*Table 5*

Time (hours)	#	MTT (%)	Acridine orange (%)	Glucose (mg%)	Albumin (gr/L)	Lactate (mg/dl)	Bile acid ( $\mu$ mol/L)	Urea (mg/dl)	Ammonia (o.d)
0	1	100	80	95	3.677	230	18.6	180	0.077
0	2	100	100	104	3.677	230	18.6	169	0.07
2	3	100	100	190	3.453	160	61.8	148	0.08
2	4	100	100	181	3.358	145	25.7	181	0.085
4	5	100	100	293	4.315	163		145	0.09
4	6	80	100	236	4.1	147	38.7	128	0.062
7	7	80	100	473	4.8	208	48.8	170	0.126
7	8	80	80	290	4.4	126	49.8	153	0.11

5

*Table 6*

Time (hours)	#	MTT (%)	Acridine orange (%)	Glucose (mg%)	Albumin (gr/L)	Lactate (mg/dl)	Bile acid ( $\mu$ mol/L)	Urea (mg/dl)	Ammonia (o.d)
0	9	100	100	98	4	230	17.6	212	0.09
0	10	100	100	101	4.09	235	13.6	222	0.09
2	11	100	100	170	4.156	142	1.56	213	0.103
2	12	80	100	142	4.06	150		171	0.055
4	13	80	100	197	3.964	145	6.6	192	0.084
4	14	100	100	136	4.09	142	8.6	200	0.088
7	15	80	50	274	4.124	138	14.6	161	0.105
7	16	80	50	154	4.538	153	14.6	192	0.114

*Table 7*

10

Time (hours)	#	MTT (%)	Acridine orange (%)	Glucose (mg%)	Albumin (gr/L)	Lactate (mg/dl)	Bile acid ( $\mu$ mol/L)	Urea (mg/dl)	Ammonia (o.d)
0	17	100	100	97	3.86	186	54.8	170	0.0865
0	18	100	100	108	3.83	198	56.8	189	0.0475
2	19	100	100	209	3.77	135	111	147	0.07
2	20	100	50	201	3.74	156	64.8	189	0.087
4	21	100	100	354	4.123	130	97	176	0.0875
4	22	100	100	289	4.25	120	8.6	160	0.115
7	23	100	100	451	4.983	117	4.6	174	0.119
7	24	100	100	418	7.826	135	4.6	155	0.098

**Table 8**

Time (hours)	#	MTT (%)	Acridine orange (%)	Glucose (mg%)	Albumin (gr/L)	Lactate (mg/dl)	Bile acid (μmol/L)	Urea (mg/dl)	Ammonia (o.d)
0	124	100	50	75	2.57	272		189	0.075
0	125	100	50	79	3.3	286		199	0.0655
2	126	100	100	290	2.8	272		180	0.06
2	127	100	80	297	1.95	273		169	0.0975
4	128	100	50	378	2.7	244		207	0.0655
4	129	100	50	478		293		190	0.0675
Over night	130	80	50	High	3.4	302		199	0.114

5

**Example 28*****Kidney MCs express Rennin, Epo and T-PA mRNA 48 hours after in vivo transplantation in rat***

Kidney MCs were prepared as described hereinabove and were transplanted in the peritoneal cavity of a rat. Following 48 hours the kidney  
 10 MCs were removed and analyzed by RT PCR for the expression of Rennin, Epo and T-PA mRNAs as is compared to the expression of these mRNAs in kidney MCs at time zero.

Reverse transcription was effected by incubating 1 μg RNA (about 10 μl), 0.5 μg of Oligo-dT (1 μl, Promega) and RNase free H<sub>2</sub>O (In a total  
 15 volume of 15 μl) for 5 minutes at 70 °C. The mixture was cooled on ice and the following ingredients were added: 5 μl RT buffer (Promega), 5 μl of dNTPs mix (10 mM, Promega), 20 units of RNAsin (Promega) and 100 units of MLV-Reverse Transcriptase (Promega). RNase free H<sub>2</sub>O was added to a final volume of 50 μl. The reactions were incubated at 42 °C for  
 20 60 minutes.

For PCR amplification a mixture containing 2.5 μl of 10x reaction buffer, 0.2 mM dNTPs, 1.5 mM MgCl<sub>2</sub>, 2 μl single strand DNA from RT reaction, 0.6 mM (1 μl) of each primer (upstream and downstream), 2.5



79

units (0.5  $\mu$ l) Taq DNA polymerase (Promega) and H<sub>2</sub>O to complete the volume to 25  $\mu$ l were mixed. Cycling conditions were: 94 °C 45 seconds, 54 °C 60 seconds and 74 °C 2 minutes.

The following amplification primer pairs were employed. For  
5 amplification of a 657 bp product of rennin cDNA Rennin1 5'-  
GCTTTGGACGAATCTTGC-3' (SEQ ID NO:7) and Rennin2 5'-  
AATGTTGAGGGTCACTGC-3' (SEQ ID NO:8) were employed. For  
amplification of a 325 bp product of Epo cDNA Epo1 5'-  
ACCACTCCCAACCCTCATCAA-3' (SEQ ID NO:9) and Epo2 5'-  
10 CGTCCAGCACCCCGTAAATAG-3' (SEQ ID NO:10) were employed.  
For amplification of a 493 bp product of T-PA cDNA T-PA1: 5'-  
GCAGAAAATGGGGCTGAA-3' (SEQ ID NO:11) and T-PA2 5'-  
GTTTGTATTGCCTCAGGC-3' (SEQ ID NO:12) were employed.

All PCR products were electrophoresed through a 1.5 % Agarose gel  
15 (BRL) in 0.5 X TBE at room temperature under 100 V. The results are  
shown in Figure 29. As seen, levels of rennin raise after 48 hours, while  
levels of erithropoietin and T-PA drop.

### *Example 30*

*Anhepatic animals show almost normal behavior when connected to a*  
20 *hepato-renal device*

A Lewis rat (241 grams in weight) was connected to an  
extracorporeal device containing both kidney and liver MCs according to  
the present invention through the iliac vein and the carotid artery. A  
Harvard pump, prewashed with 70 % ethanol, saline and saline containing  
25 200 units heparin was used to circulate the rat's blood through the device at  
a rate of 0.5 ml per minute. The device included two a 0.2  $\mu$ m  
polycarbonate membrane sandwich which contained total of 9.7 grams liver  
MCs, 0.5 grams kidney MCs and 13 ml medium containing blood of a  
donor rat. The medium contained 95 ml hemosol, 5 ml 5.88 % HCO<sub>3</sub>, 280

mg% glucose and 4 % dextrane, was saturated with 5% CO<sub>2</sub> atmosphere and supplemented with antibiotics and Hepes buffer. Three days later the rat was hepatectomized (3.05 grams liver removed). The rat was connected to the device for 35 hours post hepatectomy in coma stage 1. No ventilation was employed. Post mortem analysis revealed non-massive abdominal bleeding. The spleen, kidneys and pancreas seemed apparently normal. Rat had a yellow color and yellow urine. Samples were drawn through the first five hours post hepatectomy and analyzed as detailed in Table 9 below. 8µl vitamin k and 0.4 ml 25 % manitol were injected to the rat two hours post hepatectomy.

Thus, every hour, four samples were taken and used each to determine hematocrit (Htc), pH, pCO<sub>2</sub>, pO<sub>2</sub>, bicarbonate (HCO<sub>3</sub> mM) and glucose. Samples were derived from arterial blood entering the device (Art), blood leaving the device (Bio), dialysis medium entering the device (Min) and dialysis medium leaving the device (mout). Blood gases were measured using a gas analyzer (ABL-330 Radiometer Copenhagen). Blood glucose was measured using a standard portable glucose meter (Elite). In addition, coma stage (C.S.), respiration rate (Resp rate) and body temperature (B.T.) were also recorded every hour during the course of the experiment.

*Table 9*

Time (min)	Sample	Site	Htc	pH	pCO <sub>2</sub>	pO <sub>2</sub>	HCO <sub>3</sub>	Glucose UNITS	Resp rate	Coagulation (in 20 min)	C.S	B.T
0	1	Art	35	7.469	42.6	112.6	30.8	62	90	100 %	1	32.34
	2	Bio	49	7.315	43.9	63.8	21.9	145				
	Med 1	Min		7.707	28.4	151.7	36.4	277				
	Med 11	Mout		7.481	35.4	106.6	26.3	244				
60		Art	37	7.475	40.7	107.6	29.9	74	100		0-1	34.13
		Bio	36	7.401	47.7	80.6	29.2	93				
		Min		7.718	28.4	151.2	37.5	268				
		Mout		7.614	34.5	121.1	35.4	250				
120	3	Art	35	7.472	39.9	102.6	29	85	96		0-1	34.44
	4	Bio	36	7.316	55.2	63.6	27.5	144				
	Med 2	Min		7.709	27.8	149.2	35.9	277				
	Med 22	Mout		7.492	41	103.2	31.3	230				
180		Art	34.4	7.503	36.7	103.9	28.8	77	88		0-1	34.8
		Bio	37	7.355	53.1	64.5	29.1	133				
		Min		7.697	28.9	149.4	36.2	275				
		Mout		7.388	52.2	77.9	31	230				
300	5	Art	36	7.48	38.7	98.3	28.7	85	114		0-1	34.8
	6	Bio	37	7.396	46.7	58.4	28.3	122				
	Med 3	Min		7.7	28.3	147.4	35.8	278				
	Med 33	Mout		7.376	52.6	73.4	30.4	213				

Although the invention has been described in conjunction with  
5 specific embodiments thereof, it is evident that many alternatives,  
modifications and variations will be apparent to those skilled in the art.  
Accordingly, it is intended to embrace all such alternatives, modifications  
and variations that fall within the spirit and broad scope of the appended  
claims.

## WHAT IS CLAIMED IS:

1. A device for performing a biological modification of a fluid, the device comprising:
  - (a) a chamber having an inlet for intake of the fluid and an outlet for outflow of the fluid; and
  - (b) a collection of liver micro-organ cultures for performing the biological modification of the fluid, each individual liver micro-organ culture of said collection including liver cells and having dimensions, such that liver cells positioned deepest within said individual liver culture are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby basic *in vivo* liver micro-architecture within each individual micro-organ culture is maintained, said collection of liver micro-organ cultures being located within said chamber and said collection of liver micro-organ cultures being in contact with at least a portion of the fluid flowing through said chamber.
2. The device of claim 1, wherein said liver micro-organ cultures are prepared from at least a portion of a liver which has been cryo-preserved.
3. The device of claim 1, wherein said collection of liver micro-organ cultures is provided within a continuous liver planar organ formed by co-culturing liver-derived cells in presence of said collection of liver micro-organ cultures, such that said continuous liver planar organ is formed from an admixture of cells derived from said micro-organ cultures and said liver-derived cells.

4. The device of claim 1, wherein said collection of liver micro-organ cultures is encapsulated by a sheet of a biocompatible polymer, said sheet being located within said chamber.

5. The device of claim 4, wherein said sheet has a first dimension in a range of from about 10 cm to about 90 cm, a second dimension in a range of from about 10 cm to about 90 cm and a third dimension in a range of from about 300 micrometers to about 900 micrometers.

6. The device of claim 4, wherein a plurality of said sheets are incorporated substantially parallel in orientation within said chamber.

7. The device of claim 1, further comprising a porous membrane located substantially within said chamber, said membrane effecting said contact of the fluid and said collection of liver micro-organ-cultures.

8. The device of claim 7, wherein said membrane permits passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 250,000 Da.

9. The device of claim 7, wherein said membrane restricts passage therethrough of white blood cells and red blood cells.

10. The device of claim 1, further comprising a plurality of tubes for connection to a subject containing the fluid to be biologically modified, at least one of said tubes being connected to said inlet and at least a second of said tubes being connected to said outlet.

11. The device of claim 1, wherein said collection of liver micro-organ cultures is characterized by being cryo-preserved before being located within said chamber.

12. The device of claim 4, wherein said sheet is characterized by being located within said chamber.

13. A device for performing a biological modification of a fluid of a subject, comprising:

- (a) a chamber having an inlet for intake of the fluid and an outlet for outflow of the fluid;
- (b) a collection of liver micro-organ cultures for performing the biological modification of the fluid, each individual liver micro-organ culture of said collection including liver cells and having dimensions, such that liver cells positioned deepest within said individual liver culture are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby *in vivo* basic liver micro-architecture within each individual micro-organ culture is maintained, said collection of liver micro-organ cultures being located within said chamber and said collection of liver micro-organ cultures being in contact with at least a portion of the fluid flowing through said chamber;
- (c) a first tube having first and second ends, said first end for coupling to the subject for receiving the fluid from the subject, said second end for to said inlet; and
- (d) a second tube having first and second ends, said first end for coupling to said outlet and said second end for coupling to the



subject to return the fluid to the subject after the biological modification.

14. The device of claim 13, wherein said liver micro-organ cultures are prepared from at least a portion of a liver which has been cryo-preserved.

15. The device of claim 13, wherein said collection of liver micro-organ cultures is provided within a continuous liver planar organ formed by co-culturing liver-derived cells in presence of said collection of liver micro-organ cultures, such that said continuous liver planar organ is formed from an admixture of cells derived from said micro-organ cultures and said liver-derived cells.

16. The device of claim 13, wherein a plurality of said sheets are incorporated substantially parallel in orientation within said chamber.

17. The device of claim 16, wherein said sheet has a first dimension in a range of from about 10 cm to about 90 cm, a second dimension in a range of from about 10 cm to about 90 cm and a third dimension in a range of from about 300 micrometers to about 900 micrometers.

18. The device of claim 16, wherein a plurality of said sheets are incorporated substantially parallel in orientation within said chamber.

19. The device of claim 13, further comprising a porous membrane located substantially within said chamber, said membrane effecting said contact of the fluid and said collection of liver micro-organ cultures.

20. The device of claim 19, wherein said membrane permits passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 250,000 Da.

21. The device of claim 19, wherein said membrane restricts passage therethrough of white blood cells and red blood cells.

22. The device of claim 19, wherein said sheet is characterized by being cryo-preserved before being located substantially within said chamber.

23. A method of performing a biological modification of a fluid from a subject, the method comprising the step of perfusing a chamber containing a collection of liver micro-organ cultures with the fluid from the subject, such that said collection of liver micro-organ cultures performs the biological modification on the fluid, wherein each individual liver micro-organ culture of said collection includes liver cells and has dimensions, such that liver cells positioned deepest within said individual liver culture are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby *in vivo* basic liver micro-architecture is maintained within each individual micro-organ culture.

24. The method of claim 23, further comprising the step of cryo-preserving at least a portion of a liver prior to preparation of said micro-organ cultures for installation within said perfusion chamber.

25. The method of claim 23, wherein the fluid is blood.

26. The device of claim 23, wherein said collection of liver micro-organ cultures is provided within a continuous liver planar organ formed by co-culturing liver-derived cells in presence of said collection of liver micro-organ cultures, such that said continuous liver planar organ is formed from said micro-organ cultures and an admixture of liver-derived cells.

27. The method of claim 23, wherein said collection of liver micro-organ cultures is encapsulated by a sheet of a biocompatible polymer, said sheet being located within said chamber.

28. The method of claim 27, wherein said sheet has a first dimension in a range of from about 10 cm to about 90 cm, a second dimension in a range of from about 10 cm to about 90 cm and a third dimension in a range of from about 300 micrometers to about 900 micrometers.

29. The method of claim 27, wherein a plurality of said sheets are incorporated substantially parallel in orientation within said chamber.

30. The method of claim 23, wherein said chamber includes a porous membrane located therein, said membrane effecting said contact of the fluid and said collection of liver micro-organ cultures.

31. The method of claim 30, wherein said membrane permits passage therethrough of particles having a molecular weight from about 10,000 Da to about 250,000 Da.

32. The method of claim 30, wherein said membrane restricts passage therethrough of white blood cells and red blood cells.

33. The method of claim 30, wherein said sheet is characterized by being cryo-preserved before being located substantially within said chamber.

34. The method of claim 23, further comprising the step of returning the fluid to the subject.

35. The method of claim 34, further comprising the step of returning at least one product secreted by said collection of liver micro-organ cultures to the subject.

36. A method of preparing a continuous planar organ comprising the steps of:

- (a) obtaining a collection of individual micro-organ cultures of an organ, such that each of said individual micro-organ culture of said collection includes cells and has dimensions, such that cells positioned deepest within said individual micro-organ culture are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby *in vivo* architecture is maintained within each individual micro-organ culture; and
- (b) adding a suspension of cells onto said micro-organ cultures and co-culturing said suspension of cells in presence of said collection of micro-organ cultures, such that the continuous planar organ is formed from an admixture of cells derived from said micro-organ cultures and said cells in suspension.

37. The method of claim 36, further comprising the step of cryo-preserved at least a portion of an organ prior to obtaining said collection of individual micro-organ cultures therefrom.

38. A method of preparing a continuous liver planar organ comprising the steps of:

- (a) obtaining a collection of individual liver micro-organ cultures, such that each of said individual micro-organ culture of said collection includes liver cells and has dimensions, such that cells positioned deepest within said individual micro-organ culture are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby *in vivo* basic liver architecture within each individual micro-organ culture is maintained; and
- (b) adding a suspension of liver-derived cells onto said liver micro-organ cultures and co-culturing said suspension of cells in presence of said collection of liver micro-organ cultures, such that the continuous planar liver organ is formed from an admixture of cells derived from said micro-organ cultures and said liver-derived cells.

39. The method of claim 38, further comprising the step of cryo-preserving at least a portion of a liver prior to obtaining said collection of individual liver micro-organ cultures therefrom.

40. A device for performing a biological modification of a fluid, the device comprising:

- (a) a chamber having an inlet for intake of the fluid and an outlet for outflow of the fluid; and
- (b) a collection of micro-organ cultures of an organ for performing the biological modification of the fluid, each individual micro-organ culture of said collection including cells and having dimensions, such that cells positioned deepest

within said individual micro-organ culture are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby *in vivo* organ architecture of organ units is maintained within each individual micro-organ culture, said collection of micro-organ cultures being located within said chamber and said collection of micro-organ cultures being in contact with at least a portion of the fluid flowing through said chamber.

41. The device of claim 40, wherein said collection of micro-organ cultures of said organ are prepared from a cryopreserved portion of said organ.

42. The device of claim 40, wherein said collection of micro-organ cultures is provided within a continuous planar organ formed by co-culturing cells in suspension in presence of said collection of micro-organ cultures, such that said continuous planar organ is formed from an admixture of cells derived from said micro-organ cultures and said cells in suspension.

43. The device of claim 40, wherein said collection of micro-organ cultures is encapsulated by a sheet of a biocompatible polymer, said sheet being located within said chamber.

44. The device of claim 43, wherein said sheet has a first dimension in a range of from about 10 cm to about 90 cm, a second dimension in a range of from about 10 cm to about 90 cm and a third dimension in a range of from about 300 micrometers to about 900 micrometers.



45. The device of claim 43, wherein a plurality of said sheets are incorporated substantially parallel in orientation within said chamber.

46. The device of claim 40, further comprising a porous membrane located substantially within said chamber, said membrane effecting said contact of the fluid and said collection of micro-organ cultures.

47. The device of claim 46, wherein said membrane permits passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 250,000 Da.

48. The device of claim 46, wherein said membrane restricts passage therethrough of white blood cells and red blood cells.

49. The device of claim 40, further comprising a plurality of tubes for connection to a subject containing the fluid to be biologically modified, at least one of said tubes being connected to said inlet and at least a second of said tubes being connected to said outlet.

50. The device of claim 40, wherein said collection of micro-organ cultures is characterized by being cryo-preserved before being located within said chamber.

51. The device of claim 42, wherein said sheet is characterized by being cryo-preserved before being located within said chamber.

52. A device for performing a biological modification of a fluid of a subject, comprising:

- (a) a chamber having an inlet for intake of the fluid and an outlet for outflow of the fluid;
- (b) a collection of micro-organ cultures of an organ for performing the biological modification of the fluid, each individual micro-organ culture of said collection including cells and having dimensions, such that cells positioned deepest within said individual micro-organ culture are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby *in vivo* organ architecture of organ units is maintained within each individual micro-organ culture, said collection of micro-organ cultures being located within said chamber and said collection of micro-organ cultures being in contact with at least a portion of the fluid flowing through said chamber;
- (c) a first tube having first and second ends, said first end for coupling to the subject for receiving the fluid from the subject, said second end for coupling to said inlet; and
- (d) a second tube having first and second ends, said first end for coupling to said outlet and said second end for coupling to the subject to return the fluid to the subject after the biological modification.

53. The device of claim 52, wherein said collection of micro-organ cultures of said organ are prepared from a cryo-preserved portion of said organ.

54. The device of claim 52, wherein said collection of micro-organ cultures is provided within a continuous planar organ formed by co-culturing cells in suspension in presence of said collection of micro-organ

cultures, such that said continuous planar organ is formed from an admixture of cells derived from said micro-organ cultures and said cells in suspension.

55. The device of claim 52, wherein said collection of micro-organ cultures is encapsulated by a sheet of a biocompatible polymer, said sheet being located within said chamber.

56. The device of claim 55, wherein said sheet has a first dimension in a range of from about 10 cm to about 90 cm, a second dimension in a range of from about 10 cm to about 90 cm and a third dimension in a range of from about 300 micrometers to about 900 micrometers.

57. The device of claim 55, wherein a plurality of said sheets are incorporated substantially parallel in orientation within said chamber.

58. The device of claim 52, further comprising a porous membrane located substantially within said chamber, said membrane effecting said contact of the fluid and said collection of micro-organ cultures.

59. The device of claim 58, wherein said membrane permits passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 250,000 Da.

60. The device of claim 58, wherein said membrane restricts passage therethrough of white blood cells and red blood cells.

61. The device of claim 58, wherein said sheet is characterized by being cryo-preserved before being located substantially within said chamber.

62. A method of performing a biological modification of a fluid from a subject, the method comprising the step of perfusing a chamber containing a collection of micro-organ cultures of an organ with the fluid from the subject, such that said collection of micro-organ cultures performs the biological modification on the fluid, wherein each individual micro-organ culture of said collection includes cells and has dimensions, such that cells positioned deepest within said individual micro-organ culture are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby *in vivo* organ architecture of organ units is maintained within each individual micro-organ culture.

63. The method of claim 62, further comprising the step of cryo-preserving at least a portion of an organ prior to preparing said collection of micro-organ cultures therefrom.

64. The method of claim 62, wherein the fluid is blood.

65. The device of claim 62, wherein said collection of micro-organ cultures is provided within a continuous planar organ formed by co-culturing cells in suspension derived in presence of said collection of micro-organ cultures, such that said continuous planar organ is formed from an admixture of cells derived from said micro-organ cultures and said cells in suspension.

66. The method of claim 62, wherein said collection of micro-organ cultures is encapsulated by a sheet of a biocompatible polymer, said sheet being located within said chamber.

67. The method of claim 66, wherein said sheet has a first dimension in a range of from about 10 cm to about 90 cm, a second dimension in a range of from about 10 cm to about 90 cm and a third dimension in a range of from about 300 micrometers to about 900 micrometers.

68. The method of claim 66, wherein a plurality of said sheets are incorporated substantially parallel in orientation within said chamber.

69. The method of claim 62, wherein said chamber includes a porous membrane located therein, said membrane effecting said contact of the fluid and said collection of micro-organ cultures.

70. The method of claim 69, wherein said membrane permits passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 250,000 Da.

71. The method of claim 69, wherein said membrane restricts passage therethrough of white blood cells and red blood cells.

72. The method of claim 69, wherein said sheet is characterized by being cryo-preserved before being located substantially within said chamber.

73. The method of claim 69, further comprising the step of returning the fluid to the subject.

74. The method of claim 73, further comprising the step of returning at least one product secreted by said collection of micro-organ cultures to the subject.

75. An extra-corporeal device for providing a subject with one or more hepatic functions, the device comprising:

- (a) a chamber being located extra-corporeally to the subject, said chamber being equipped with a first tube and a second tube being in fluid communication with the circulatory system of the subject, so that blood flows from the subject through the first tube into the chamber and from the chamber through the second tube to the subject; and
- (b) a plurality of liver micro-organ cultures being contained within said chamber, such that said plurality of liver micro-organ cultures are in contact with at least a portion of said subject's blood as it flows through said chamber, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof.

76. The device of claim 75, wherein said plurality of liver micro-organ cultures are prepared from at least a portion of a liver which has been cryo-preserved.



77. The device of claim 75, further comprising:

- (c) biocompatible membranes which hold said a plurality of liver micro-organ cultures within said chamber, said membranes being permeable to blood components and to liver secretions.

78. The device of claim 77, wherein said membranes are polycarbonate membranes.

79. The device of claim 75, further comprising:

- (d) cells derived from a cell suspension co-cultured with said plurality of liver micro-organ cultures such that a continuous planar organ is formed.

80. The device of claim 79, wherein said derived from a cell suspension are liver derived cells.

81. The device of claim 75, wherein said plurality of liver micro-organ cultures is characterized by being cryo-preserved and thawed before being located within said chamber.

82. An intra-corporeal device for providing a subject with one or more hepatic functions, the device comprising:

- (a) an intrabodily transplantable chamber, said chamber being constructed of one or more bio-compatible membranes being sealed around all edges so as to form a sealed bag, said membranes being selected so as to allow vascularization into said bag following implantation within the subject; and
- (b) a plurality of liver micro-organ cultures being contained within said chamber, such that said plurality of liver micro-organ cultures are in contact with at least a portion of said

subject's blood as said vascularization occurs, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof.

83. The device of claim 82, wherein said plurality of liver micro-organ cultures are prepared from at least a portion of a liver which has been cryo-preserved.

84. The device of claim 82, wherein said membranes being permeable to blood components and to liver secretions.

85. The device of claim 84, wherein said membranes are polycarbonate membranes.

86. The device of claim 82, further comprising:

- (d) cells derived from a cell suspension being co-cultured with said plurality of liver micro-organ cultures such that a continuous planar organ is formed.

87. The device of claim 86, wherein said cells derived from a cell suspension are liver derived cells.

88. The device of claim 84, wherein said plurality of liver micro-organ cultures are arranged in layers.

89. The device of claim 84, wherein said membranes permit passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 500,000 Da.

90. The device of claim 82, wherein said plurality of liver micro-organ cultures is characterized by being cryo-preserved before being located within said chamber

91. A method for providing a subject with one or more hepatic functions, the method comprising the steps of:

- (a) providing a chamber being equipped with a first tube and a second tube;
- (b) containing in said chamber a plurality of liver micro-organ cultures such that said plurality of liver micro-organ cultures, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof; and
- (c) while being located extra-corporeally to the subject, forming a fluid communication between said chamber and the circulatory system of the subject, so that blood flows from the

100

subject through the first tube into the chamber and from the chamber through the second tube to the subject, such that said liver micro-organ cultures are in contact with at least a portion of said subject's blood as it flows through said chamber.

92. The method of claim 91, further comprising the step of cryo-preserving at least a portion of a liver prior to preparing said plurality of liver micro-organ cultures therefrom.

93. The method of claim 91, wherein bio compatible membranes hold said a plurality of liver micro-organ cultures within said chamber, said membranes being permeable to blood components and to liver secretions.

94. The device of claim 93, wherein said membranes are polycarbonate membranes.

95. The method of claim 91, further comprising the step of co-culturing cells derived from a cell suspension with said plurality of liver micro-organ cultures such that a continuous planar organ is formed.

96. The method of claim 95, wherein said cells derived from a cell suspension are liver derived cells.

97. The method of claim 91, wherein said plurality of liver micro-organ cultures is characterized by being cryo-preserved and thawed before being located within said chamber

98. A method for providing a subject with one or more hepatic functions, the method comprising the steps of:

- (a) providing an intrabodily transplantable chamber, said chamber being constructed of one or more bio-compatible membranes

101

being sealed around all edges so as to form a sealed bag, said membranes being selected so as to allow vascularization into said bag following implantation within the subject; and

- (b) containing within said chamber a plurality of liver micro-organ cultures, such that said plurality of liver micro-organ cultures are in contact with at least a portion of said subject's blood as said vascularization occurs, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof; and
- (c) implanting said chamber within a subject.

99. The method of claim 98, further comprising the step of cryo-preserving at least a portion of a liver prior to preparing said plurality of liver micro-organ cultures therefrom.

100. The method of claim 98, wherein said membranes being permeable to blood components and to liver secretions.

101. The method of claim 100, wherein said membranes are polycarbonate membranes.

102

102. The method of claim 98, further comprising the step of co-culturing cells derived from a cell suspension with said plurality of liver micro-organ cultures such that a continuous planar organ is formed.

103. The method of claim 102, wherein said cells derived from a cell suspension are liver derived cells.

104. The method of claim 100, wherein said plurality of liver micro-organ cultures are arranged in layers.

105. The method of claim 100, wherein said membranes permit passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 500,000 Da.

106. The method of claim 98, wherein said plurality of liver micro-organ cultures is characterized by being cryo-preserved and thawed before being located within said chamber

107. An extra-corporeal device for providing a subject with one or more renal functions, the device comprising:

- (a) a chamber being located extra-corporeally to the subject, said chamber being equipped with a first tube and a second tube being in fluid communication with the circulatory system of the subject, so that blood flows from the subject through the first tube into the chamber and from the chamber through the second tube to the subject; and
- (b) a plurality of kidney micro-organ cultures being contained within said chamber, such that said plurality of kidney micro-organ cultures are in contact with at least a portion of said subject's blood as it flows through said chamber, wherein



103

cells positioned deepest within an individual micro-organ culture of said plurality of micro organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof.

108. The device of claim 107, wherein said plurality of kidney micro-organ cultures are prepared from at least a portion of a kidney which has been cryo-preserved.

109. The device of claim 107, further comprising:

- (c) biocompatible membranes which hold said a plurality of kidney micro-organ cultures within said chamber, said membranes being permeable to blood components and to kidney secretions.

110. The device of claim 109, wherein said membranes are polycarbonate membranes.

111. The device of claim 107, further comprising:

- (d) cells derived from a cell suspension co-cultured with said plurality of kidney micro-organ cultures such that a continuous planar organ is formed.

112. The device of claim 111, wherein said cells derived from a cell suspension are kidney derived cells.

113. The device of claim 107, further comprising a hemodialysis unit being in fluid communication with said chamber for dialyzing said subject's blood.

114. The device of claim 107, wherein said plurality of kidney micro-organ cultures is characterized by being cryo-preserved and thawed before being located within said chamber.

115. An intra-corporeal device for providing a subject with one or more renal functions, the device comprising:

- (a) an intrabodily transplantable chamber, said chamber being constructed of one or more bio-compatible membranes being sealed around all edges so as to form a sealed bag, said membranes being selected so as to allow vascularization into said bag following implantation within the subject; and
- (b) a plurality of kidney micro-organ cultures being contained within said chamber, such that said plurality of kidney micro-organ cultures are in contact with at least a portion of said subject's blood as said vascularization occurs, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures

105

of diffusional nutrition and oxygenation and prevention of necrosis thereof.

116. The device of claim 115, wherein said plurality of kidney micro-organ cultures are prepared from at least a portion of a kidney which has been cryo-preserved.

117. The device of claim 115, wherein said membranes being permeable to blood components and to kidney secretions.

118. The device of claim 117, wherein said membranes are polycarbonate membranes.

119. The device of claim 115, further comprising:

(d) cells derived from a cell suspension being co-cultured with said plurality of kidney micro-organ cultures such that a continuous planar organ is formed.

120. The device of claim 119, wherein said cells derived from a cell suspension are kidney derived cells.

121. The device of claim 117, wherein said plurality of kidney micro-organ cultures are arranged in layers.

122. The device of claim 117, wherein said membranes permit passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 500,000 Da.

123. The device of claim 115, wherein said chamber includes a dialysis bag therein containing a replaceable dialysis buffer, said dialysis

bag having a tube in fluid communication therewith, said tube being supplemented with a valve at a distal end thereof, said tube being selected of sufficient length such that said valve being positionable outside the subject's body so as to enable replacement therethrough of said dialysis buffer.

124. The device of claim 115, wherein said plurality of kidney micro-organ cultures is characterized by being cryo-preserved before being located within said chamber.

125. A method for providing a subject with one or more renal functions, the method comprising the steps of:

- (a) providing a chamber being equipped with a first tube and a second tube;
- (b) containing in said chamber a plurality of kidney micro-organ cultures such that said plurality of kidney micro-organ cultures, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro-organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof; and
- (c) while being located extra-corporeally to the subject, forming a fluid communication between said chamber and the circulatory system of the subject, so that blood flows from the subject through the first tube into the chamber and from the

chamber through the second tube to the subject, such that said kidney micro-organ cultures are in contact with at least a portion of said subject's blood as it flows through said chamber.

126. The method of claim 125, further comprising the step of cryo-preserving at least a portion of a kidney prior to preparing said plurality of kidney micro-organ cultures therefrom.

127. The method of claim 125, wherein bio compatible membranes hold said a plurality of kidney micro-organ cultures within said chamber, said membranes being permeable to blood components and to kidney secretions.

128. The device of claim 127, wherein said membranes are polycarbonate membranes.

129. The method of claim 125, further comprising the step of co-culturing cells-derived from a cell suspension with said plurality of kidney micro-organ cultures such that a continuous planar organ is formed.

130. The method of claim 129, wherein said cells derived from a cell suspension are kidney derived cells.

131. The method of claim 125, further comprising the step of providing a hemodialysis unit in fluid communication with said chamber for dialyzing said subject's blood.

132. The method of claim 125, wherein said plurality of kidney micro-organ cultures is characterized by being cryo-preserved before being located within said chamber.

133. A method for providing a subject with one or more renal functions, the method comprising the steps of:

- (a) providing an intrabodily transplantable chamber, said chamber being constructed of one or more bio-compatible membranes being sealed around all edges so as to form a sealed bag, said membranes being selected so as to allow vascularization into said bag following implantation within the subject; and
- (b) containing within said chamber a plurality of kidney micro-organ cultures, such that said plurality of kidney micro-organ cultures are in contact with at least a portion of said subject's blood as said vascularization occurs, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof; and
- (c) implanting said chamber within a subject.

134. The method of claim 133, further comprising the step of cryo-preserving at least a portion of a kidney prior to preparing said plurality of kidney micro-organ cultures therefrom.



135. The method of claim 133, wherein said membranes being permeable to blood components and to kidney secretions.

136. The method of claim 135, wherein said membranes are polycarbonate membranes.

137. The method of claim 133, further comprising the step of co-culturing cells derived from a cell suspension with said plurality of kidney micro-organ cultures such that a continuous planar organ is formed.

138. The method of claim 137, wherein said cells derived from a cell suspension are kidney derived cells.

139. The method of claim 135, wherein said plurality of kidney micro-organ cultures are arranged in layers.

140. The method of claim 135, wherein said membranes permit passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 500,000 Da.

141. The method of claim 133, further comprising the step of including in said chamber a dialysis bag containing a replaceable dialysis buffer, said dialysis bag having a tube in fluid communication therewith, said tube being supplemented with a valve at a distal end thereof, said tube being selected of sufficient length such that said valve being positionable outside the subject's body so as to enable replacement therethrough of said dialysis buffer.

142. The method of claim 133, wherein said plurality of kidney micro-organ cultures is characterized by being cryo-preserved and thawed before being located within said chamber.

143. An extra-corporeal device for providing a subject with one or more renal and hepatic functions, the device comprising:

- (a) a chamber being located extra-corporeally to the subject, said chamber being equipped with a first tube and a second tube being in fluid communication with the circulatory system of the subject, so that blood flows from the subject through the first tube into the chamber and from the chamber through the second tube to the subject; and
- (b) a plurality of kidney- and liver micro-organ cultures being contained within said chamber, such that said plurality of kidney- and liver micro-organ cultures are in contact with at least a portion of said subject's blood as it flows through said chamber, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro organ

111

cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof.

144. The device of claim 143, wherein said plurality of kidney- and liver micro-organ cultures are prepared from at least a portion of a kidney and at least a portion of a liver which have been cryo-preserved.

145. The device of claim 143, further comprising:

- (c) bio compatible membranes which hold said a plurality of kidney- and liver micro-organ cultures within said chamber, said membranes being permeable to blood components and to kidney and liver secretions.

146. The device of claim 145, wherein said membranes are polycarbonate membranes.

147. The device of claim 143, further comprising:

- (d) cells derived from a cell suspension co-cultured with said plurality of kidney- and liver micro-organ cultures such that a continuous planar organ is formed.

148. The device of claim 147, wherein said cells derived from a cell suspension are selected from the group consisting of kidney derived cells and liver derived cells.

149. The device of claim 145, further comprising a hemodialysis unit being in fluid communication with said chamber for dialyzing said subject's blood.

150. The device of claim 143, wherein said plurality of kidney- and liver micro-organ cultures is characterized by being cryo-preserved before being located within said chamber.

151. An intra-corporeal device for providing a subject with one or more renal and hepatic functions, the device comprising:

- (a) an intrabodily transplantable chamber, said chamber being constructed of one or more bio-compatible membranes being sealed around all edges so as to form a sealed bag, said membranes being selected so as to allow vascularization into said bag following implantation within the subject; and
- (b) a plurality of kidney- and liver micro-organ cultures being contained within said chamber, such that said plurality of kidney- and liver micro-organ cultures are in contact with at least a portion of said subject's blood as said vascularization occurs, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof.

152. The device of claim 151, wherein at least a portion of a kidney and at least a portion of a liver are cryo-preserved prior to preparing said plurality of kidney and liver micro-organ cultures therefrom.

153. The device of claim 151, wherein said membranes being permeable to blood components and to kidney and liver secretions.

154. The device of claim 153, wherein said membranes are polycarbonate membranes.

155. The device of claim 151, further comprising:

- (d) cells derived from a cell suspension being co-cultured with said plurality of kidney- and liver micro-organ cultures such that a continuous planar organ is formed.

156. The device of claim 155, wherein said cells derived from a cell suspension are selected from the group consisting of kidney derived cells and liver derived cells.

157. The device of claim 153, wherein said plurality of kidney- and liver micro-organ cultures are arranged in layers.

158. The device of claim 153, wherein said membranes permit passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 500,000 Da.

159. The device of claim 151, wherein said chamber includes a dialysis bag therein containing a replaceable dialysis buffer, said dialysis bag having a tube in fluid communication therewith, said tube being supplemented with a valve at a distal end thereof, said tube being selected

of sufficient length such that said valve being positionable outside the subject's body so as to enable replacement therethrough of said dialysis buffer.

160. The device of claim 151, wherein said plurality of kidney- and liver micro-organ cultures is characterized by being cryo-preserved and thawed before being located within said chamber.

161. A method for providing a subject with one or more renal and hepatic functions, the method comprising the steps of:

- (a) providing a chamber being equipped with a first tube and a second tube;
- (b) containing in said chamber a plurality of kidney- and liver micro-organ cultures such that said plurality of kidney- and liver micro-organ cultures, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof; and
- (c) while being located extra-corporeally to the subject, forming a fluid communication between said chamber and the circulatory system of the subject, so that blood flows from the subject through the first tube into the chamber and from the chamber through the second tube to the subject, such that said



115

kidney- and liver micro-organ cultures are in contact with at least a portion of said subject's blood as it flows through said chamber.

162. The method of claim 161, further comprising the step of cryo-preserving at least a portion of a kidney and at least a portion of a liver prior to preparing said plurality of kidney- and liver micro-organ cultures therefrom.

163. The method of claim 161, wherein bio compatible membranes hold said a plurality of kidney- and liver micro-organ cultures within said chamber, said membranes being permeable to blood components and to kidney and liver secretions.

164. The device of claim 163, wherein said membranes are polycarbonate membranes.

165. The method of claim 161, further comprising the step of co-culturing cells derived from a cell suspension with said plurality of kidney- and liver micro-organ cultures such that a continuous planar organ is formed.

166. The method of claim 165, wherein said cells derived from a cell suspension are selected from the group consisting of kidney derived cells and liver derived cells.

167. The method of claim 161, further comprising the step of providing a hemodialysis unit in fluid communication with said chamber for dialyzing said subject's blood.

168. The method of claim 161, wherein said plurality of kidney- and liver micro-organ cultures is characterized by being cryo-preserved and thawed before being located within said chamber.

169. A method for providing a subject with one or more renal and hepatic functions, the method comprising the steps of:

- (a) providing an intrabodily transplantable chamber, said chamber being constructed of one or more bio-compatible membranes being sealed around all edges so as to form a sealed bag, said membranes being selected so as to allow vascularization into said bag following implantation within the subject; and
- (b) containing within said chamber a plurality of kidney- and liver micro-organ cultures, such that said plurality of kidney- and liver micro-organ cultures are in contact with at least a portion of said subject's blood as said vascularization occurs, wherein cells positioned deepest within an individual micro-organ culture of said plurality of micro organ cultures are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual micro-organ culture, thereby maintaining *in vivo* tissue architecture within each individual micro-organ culture, while, at the same time, allowing said cells positioned deepest within each individual micro-organ culture of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof; and
- (c) implanting said chamber within a subject.

170. The method of claim 169, further comprising the step of cryo-preserving at least a portion of a kidney and at least a portion of a liver

prior to preparing said plurality of kidney and liver micro-organ cultures therefrom.

171. The method of claim 169, wherein said membranes being permeable to blood components and to kidney and liver secretions.

172. The method of claim 171, wherein said membranes are polycarbonate membranes.

173. The method of claim 169, further comprising the step of co-culturing cells derived from a cell suspension with said plurality of kidney- and liver micro-organ cultures such that a continuous planar organ is formed.

174. The method of claim 173, wherein said cells derived from a cell suspension are selected from the group consisting of kidney derived cells and liver derived cells.

175. The method of claim 171, wherein said plurality of kidney- and liver micro-organ cultures are arranged in layers.

176. The method of claim 171, wherein said membranes permit passage therethrough of particles having a molecular weight less than from about 10,000 Da to about 500,000 Da.

177. The method of claim 169, further comprising the step of including in said chamber a dialysis bag containing a replaceable dialysis buffer, said dialysis bag having a tube in fluid communication therewith, said tube being supplemented with a valve at a distal end thereof, said tube being selected of sufficient length such that said valve being positionable

outside the subject's body so as to enable replacement therethrough of said dialysis buffer.

178. The method of claim 169, wherein said plurality of kidney- and liver micro-organ cultures is characterized by being cryo-preserved and thawed before being located within said chamber.

179. A method for preparing and using cryo-micro-organs, the method comprising the steps of:

- (a) cryo-preserving at least a part of an organ, so as to obtain cryo-preserved segments of said organ;
- (b) cutting said cryo-preserved segments into sections while in a cryo-preserved state;
- (c) prior to use, thawing said frozen sections, so as to obtain thawed sections; and
- (d) employing said thawed sections as micro-organs.

180. The method of claim 179, wherein cryo-preserving said at least said part of said organ, so as to obtain said cryo-preserved tissue of said organ is effected in a solution containing at least one component selected from the group consisting of DMEM, DMSO, Glycerin, trehalose, raffinose, an antibiotic, an antimycotic and glucose.

181. The method of claim 179, wherein the temperature for cryo-preservation is between zero degrees centigrade and -180 degrees centigrade.

182. The method of claim 179, wherein a thickness of said sections is between approximately 200 and approximately 400 micrometers.

183. The method of claim 179, further comprising the step of:

- (e) storing said sections at a temperature which maintains their cryo-preserved state for a period of time prior to thawing said sections.

184. The method of claim 179, wherein the step of employing said thawed sections as micro-organs is effected by:

- (i) providing a chamber;
- (ii) containing within said chamber a plurality of said sections;
- (iii) introducing into said chamber at least a portion of a subject's blood such that said plurality of thawed sections are in contact with said subject's blood, wherein cells positioned deepest within an individual thawed section of said plurality of thawed sections are at least about 100 micrometers and not more than about 225 micrometers away from a nearest surface of said individual thawed section, thereby maintaining *in vivo* tissue architecture within each individual thawed section, while, at the same time, allowing said cells positioned deepest within each individual thawed section of said plurality of micro organ cultures of diffusional nutrition and oxygenation and prevention of necrosis thereof; and
- (iv) reintroducing into said subject at least a portion of said subject's blood after it has been in contact with said thawed sections.








FIG. 1a






FIG. 1b









4/30




FIG. 1d



5/30




FIG.2a








FIG.2B

SUBSTITUTE SHEET (RULE 26)





7/30

**FIG.3a****FIG.3b**







FIG.3c



9/30





10/30


Mouse liver MCs incorporate thymidine culture

FIG.5


Albumin is produced by mouse hepatocytes in MC cultures

FIG.6





11/30


Conversion of Ammonia into Urea in Mouse Liver MC Cultures

FIG.7


Human MC liver cultures convert large ammounts of ammonia into area for long periods of time

FIG.8



12/30

Human liver Micro-Organ cultures are metabolically active




FIG.9

Cryopreserved MC liver cultures remain functional when grown at 37°C




FIG.10



13/30

Cryopreserved Human MC liver cultures remain functional  
when grown at 37°C




FIG.11

Liver-Micro-Organ cultures are metabolically active when  
encapsulated in alginate sheets




FIG.12





14/30

Mouse Liver MCs remain functional when cultured in  
100% fetal calf serum




FIG.13



15/30

Cryopreserved Liver Micro-Organ cultures are metabolically active when encapsulated in alginate sheets prior to freezing




FIG.14a Urea






FIG.14b Albumin



16/30

In vivo animals can be connected safely to the bioreactor containing MC alginate sheets.

**FIG.15****FIG.16**



120






FIG.17





18/30

**FIG.18****FIG.19**



19/30




FIG.20a




FIG.20b




FIG.20c



20/30




FIG.20d




FIG.20e








FIG.21a




FIG.21b



22/30




FIG.21c




FIG.21d



23/30




FIG.21e




FIG.22



24/30




FIG.23

COMSUMPTION OF LIGNOCAINE  
HCl BY Liver MCs




FIG.24








FIG.25a




FIG.25b



26/30




FIG.25c




FIG.25d



27/30




FIG.26a




FIG.26b



28/30




FIG.27a




FIG.27b





29/30




FIG.27c




FIG.27d



30/30



FIG.28

M    Renin    EPO    TPA  
To 48h   To 48h   To 48h



FIG.29



WO 01/07098

1  
SEQUENCE LISTING

- (1) GENERAL INFORMATION: EDUARDO MITRANI  
 (i) APPLICANT: A DEVICE AND METHOD FOR PERFORMING A  
 (ii) TITLE OF INVENTION: BIOLOGICAL MODIFICATION OF A FLUID  
 12  
 (iii) NUMBER OF SEQUENCES: 12  
 (iv) CORRESPONDENCE ADDRESS: EHRLICH, GAL c/o Anthony Castorina  
 (A) ADDRESSEE: 2001 Jefferson Davis Highway, Suite 207  
 (B) STREET: Arlington  
 (C) CITY: Virginia  
 (D) STATE: United States of America  
 (E) COUNTRY: 22202  
 (F) ZIP:  
 (v) COMPUTER READABLE FORM: 1.44 megabyte, 3.5" microdisk  
 (A) MEDIUM TYPE: Twinhead® Slimnote-890TX  
 (B) COMPUTER: MS DOS version 6.2,  
 (C) OPERATING SYSTEM: Windows 98  
 (D) SOFTWARE: Word for Windows version 6.0 converted to  
 an ASCII file  
 (vi) CURRENT APPLICATION DATA:  
 (A) APPLICATION NUMBER:  
 (B) FILING DATE:  
 (C) CLASSIFICATION:  
 (vii) PRIOR APPLICATION DATA:  
 (A) APPLICATION NUMBER:  
 (B) FILING DATE:  
 (viii) ATTORNEY/AGENT INFORMATION: EHRLICH, GAL  
 (A) NAME: IL 121  
 (B) REGISTRATION NUMBER: 00/20753  
 (C) REFERENCE/DOCKET NUMBER:  
 (ix) TELECOMMUNICATION INFORMATION: 972-3-6127676  
 (A) TELEPHONE: 972-3-6127575  
 (B) TELEFAX:  
 (C) TELEX:  
 (2) INFORMATION FOR SEQ ID NO:1:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:  
 TGAAGTGGCT GACTGCTGTG 20  
 (2) INFORMATION FOR SEQ ID NO:2:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:  
 CATCCTTGGC CTCAGCATAG 20  
 (2) INFORMATION FOR SEQ ID NO:3:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 18  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:  
 TCTGTTGCCT ACAATTCT 18  
 (2) INFORMATION FOR SEQ ID NO:4:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 18  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:  
 TAGTATATAT TCCATATT 18  
 (2) INFORMATION FOR SEQ ID NO:5:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 18  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:



WO 01/07098

2

ATAAAGAAAG GAAATCTG 18

- (2) INFORMATION FOR SEQ ID NO:6:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 18  
     (B) TYPE: nucleic acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear  
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:  
 TCACAAAGTA GGTGTCTT 18

- (2) INFORMATION FOR SEQ ID NO:7:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 18  
     (B) TYPE: nucleic acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear  
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:  
 GCTTTGGACG AATCTTGC 18

- (2) INFORMATION FOR SEQ ID NO:8:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 18  
     (B) TYPE: nucleic acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear  
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:  
 AATGTTGAGG GTCAGTGC 18

- (2) INFORMATION FOR SEQ ID NO:9:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 21  
     (B) TYPE: nucleic acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear  
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:  
 ACCACTCCCA ACCCTCATCA A 21

- (2) INFORMATION FOR SEQ ID NO:10:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 21  
     (B) TYPE: nucleic acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear  
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:  
 CGTCCAGCAC CCCGTAAATA G 21

- (2) INFORMATION FOR SEQ ID NO:11:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 18  
     (B) TYPE: nucleic acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear  
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:  
 GCAGAAAATG GGGCTGAA 18

- (2) INFORMATION FOR SEQ ID NO:12:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 18  
     (B) TYPE: nucleic acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear  
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:  
 GTTTGTATTG CCTCAGGC 18






# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: GAL EHRLICH  
G.E. EHRLICH (1995) LTD.  
28 BEZALEL STREET  
52 521 RAMAT GAN  
ISRAEL



## NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

<p>Date of Mailing (day/month/year) <b>16 JAN 2001</b> <span style="border: 1px solid black; border-radius: 50%; padding: 2px;">d</span></p>	
<p>Applicant's or agent's file reference <b>00/20753</b></p>	<p><b>FOR FURTHER ACTION</b> See paragraphs 1 and 4 below</p>
<p>International application No. <b>PCT/IL00/00424</b></p>	<p>International filing date (day/month/year) <b>19 JULY 2000</b></p>
<p>Applicant <b>YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM</b></p>	

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

<p>Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230</p>	<p>Authorized officer <b>FRANCISCO C. PRATS</b> <b>TERRY J. DEY</b> <i>TD</i> <b>PARALEGAL SPECIALIST</b> <b>TECHNOLOGY CENTER 1600</b> Telephone No. (703) 308-0150</p>
--	--



# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: GAL EHRLICH  
G.E. EHRLICH (1995) LTD.  
28 BEZALEL STREET  
52 521 RAMAT GAN  
ISRAEL

**RECEIVED**

29 JAN 2001

FILE No. 00/20753

**PCT** E. EHRLICH (1995) LTD.

## NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

Date of Mailing  
(day/month/year)

**16 JAN 2001**

Applicant's or agent's file reference  
00/20753

**FOR FURTHER ACTION** See paragraphs 1 and 4 below

International application No.  
PCT/IL00/00424

International filing date  
(day/month/year)

19 JULY 2000

Applicant

YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 *bis* 1 and 90 *bis* 3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FRANCISCO C. PRATS

Telephone No.

(703) 308-6156

**TERRY J. DEY**

**PARALEGAL SPECIALIST**

**TECHNOLOGY CENTER 1600**



# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 00/20753	<b>FOR FURTHER ACTION</b>	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/IL00/00424	International filing date ( <i>day/month/year</i> ) 19 JULY 2000	(Earliest) Priority Date ( <i>day/month/year</i> ) 23 JULY 1999
Applicant YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 2 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

### 1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☐ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (See Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. \_\_\_\_\_

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IL00/00424

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 1/00, 1/02; C02F 3/00, 3/02

US CL : 435/1.1, 347, 373, 374; 210/601, 602

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/1.1, 347, 373, 374; 210/601, 602

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST databases including USPAT, EPO, JPO, Derwent; search terms: micro-organ, liver kidney, artificial, organ, culture, slice, explant

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3,734,851 A (MATSUMURA) 22 May 1973, column 4, lines 28-53.	1-184
Y	US 5,888,720 A (MITRANI) 30 March 1999, see entire document, especially column 5, line 28 through column 6, line 17.	1-184
Y	US 5,516,680 A (NAUGHTON et al) 14 May 1996, see entire document, especially columns 54-58 (claims 1-50).	1-184
Y	US 5,759,830 A (VACANTI et al) 02 June 1998, see entire document, especially columns 5 and 6.	143-184

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*P* document published prior to the international filing date but later than the priority date claimed
*O* document referring to an oral disclosure, use, exhibition or other means	*G* document member of the same patent family

Date of the actual completion of the international search

21 NOVEMBER 2000

Date of mailing of the international search report

16 JAN 2001

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FRANCISCO C. PRATS **PARALEGAL SPECIALIST**Telephone No. (703) 308-**TECHNOLOGY CENTER 1600**



• • • • •

RECEIVED

MAY 20 2 37

DIPE/JCWS

3